Clinical Trials on Alzheimer's Disease

CTAD 2016

Montpellier '08 | Las Vegas '09 | Toulouse '10 | San Diego '11
Monte Carlo '12 | San Diego '13 | Philadelphia '14
Barcelona '15

Clinical Trials

December 8-10, 2016
SAN DIEGO

www.ctad-alzheimer.com
Scientific committee

Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Rachelle DOODY (Houston)
Bruno DUBOIS (Paris)
Howard FELDMAN (Vancouver)
Nick FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Munich)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)

Constantine G. LYKETSOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Minnesota)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Gordon WILCOCK (Oxford)
Bengt WINBLAD (Stockholm)

Congress secretariat

ANT Congrès - E-mail : ctad@ant-congres.com - Tel : + 33 (0)4 67 10 92 23
Dear Colleague,

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2015 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD. Again in 2016 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.

CTAD 2016 will highlight the latest on trying to get these trials off the ground.

Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.

We are delighted to be welcoming you to San Diego!

Organizing Commitee

Paul Aisen  
MD Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC), San Diego, USA

Jacques Touchon  
MD, PhD  
University Hospital of Montpellier, France

Bruno Vellas  
MD, PhD  
University Hospital of Toulouse, France

Mike Weiner  
MD University of California San Francisco (UCSF), USA
Keynote speakers

Paul S. Aisen has conducted therapeutic research on Alzheimer’s disease for over 25 years. After graduating from Harvard College, Cambridge, Massachusetts, Dr Aisen received his medical degree from the Columbia University College of Physicians and Surgeons in New York City and pursued his clinical training as a resident in the Department of Medicine at University Hospitals in Cleveland, Ohio, and in the Department of Medicine at Mount Sinai Hospital in New York City. He completed his fellowship in the Division of Rheumatology at the New York University Medical Center before returning to Mount Sinai Hospital as chief resident in the Department of Medicine. Dr Aisen is a diplomate of the American Board of Internal Medicine, with specialty certification in rheumatology. After 15 years on the faculty at Mount Sinai, Dr Aisen moved to Georgetown University, Washington, DC, in 1999 as professor in the departments of neurology and of medicine and became vice chair of the Department of Neurology in 2004. From 2007 until 2015 he was professor of neurosciences at the University of California, San Diego in La Jolla, California, and Director of the Alzheimer’s Disease Cooperative Study. At present he is Director of the University of Southern California Alzheimer’s Therapeutic Research Institute, located in San Diego, California. Dr Aisen has collaborated extensively with the biotech and pharmaceutical industries for many years. He has led numerous multicenter trials, and has authored more than 300 scientific papers.

Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine, received BS degrees in Biology and Electrical Engineering from Washington University, and his MD from Case Western Reserve University School of Medicine. Dr. Bateman is the Director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in the DIAN. Dr. Bateman serves as Principal Investigator of the DIAN and the Washington University DIAN Performance Site. Dr. Bateman’s laboratory investigates causes and future diagnostic tests and treatments of Alzheimer’s disease utilizing many assays and techniques from quantitative measurement of stable-isotope labeled proteins to clinical translational studies for Alzheimer’s disease. Recent awards include the Glenn Award for Research (2011), the Metlife Promising Investigator Award (2012), the Chancellor’s Entrepreneurship and Innovation Award (2013), and the MetLife Award in Medical Research (2015).

Maria Carrillo is Chief Science Officer, Medical and Scientific Relations, at the Alzheimer’s Association. Dr. Carrillo has a wide range of responsibilities, including oversight of the Association’s grantmaking process and communication of scientific findings within and outside of the organization. Dr. Carrillo directly manages several Alzheimer’s Association initiatives, including the Research Roundtable, the World-Wide Alzheimer’s Disease Neuroimaging Initiative, and the Global Alzheimer’s Association Interactive Network. She is co-author of the Alzheimer’s Association revised criteria for the diagnosis of Alzheimer’s, and the Appropriate Use Criteria for Amyloid Imaging. She is on the Advisory Committee for the World Health Organization Dementia Setting Priorities & Portfolio Analysis.

Nick Fox is Professor of Clinical Neurology and Director of the Dementia Research Centre at UCL’s Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square London. He has been involved in dementia research for over twenty years with particular interests in improving diagnosis and in using imaging biomarkers to accelerate the search for effective therapies. His group’s research includes a number of multimodal longitudinal cohort studies in sporadic and familial AD, frontotemporal dementia and normal ageing. Nick’s first degree was in Physics and Physiology from Cambridge University. He subsequently graduated with honours in medicine and surgery from the University of London and then specialised in cognitive neurology. He is an elected Fellow of the Academy of Medical Sciences and an NIHR Senior Investigator. He was a member of the Prime Minister’s Dementia Research Champions Group. He has contributed to advisory boards or steering committees for a number of clinical trials and natural history studies in dementia. He serves on the steering group of the Dementias Platform UK. He chairs UCL’s Dementia Strategy Board and co-chairs the Alzheimer’s Society UK’s Research Strategy Council.

David Michelson received his medical degree from the Albert Einstein College of Medicine in New York. He trained in psychiatry at Yale University, where he was also a chief resident and faculty member before moving to the intramural program of the NIMH in 1990. In 1996 he joined Eli Lilly, eventually assuming responsibility for the early phase clinical development group in neuroscience. In 2006 he joined Merck Research Laboratories as vice president and therapeutic area head for clinical neuroscience. He has overseen the clinical development of number of novel drugs, including atomoxetine (Strattera), tafluprost (Zioptan), suvorexant (Belsomra) and sugammadex (Bridion), as well as a number of programs in Alzheimer’s Disease, including MK-8931, the BACE inhibitor currently being studied in two large phase 3 trials.
Dr. Neil Buckholtz served as the Director of the Division of Neuroscience at the National Institute on Aging (NIA) at the National Institutes of Health (NIH). During his twenty-five year tenure at NIA, Dr. Buckholtz was responsible for developing and managing many signature extramural research programs including the Alzheimer’s disease (AD) drug discovery and development program, the preclinical drug toxicology evaluation contract, the AD Cooperative Study (ADCS), the AD Neuroimaging Initiative (ADNI), the Dominantly Inherited Alzheimer’s Network (DIAN), the Accelerating Medicines Partnership-AD, and the 2012 and 2015 AD Research Summits. He has extensive experience providing information on all aspects of AD research to media as well as to lay and professional groups. Currently, he is consulting with the NIA and other public and private entities on AD prevention, treatment, and diagnostic research strategies.

Dr. Buckholtz received his B.S. degree in psychology from the Ohio State University and his M.S. and PhD degrees in physiological psychology from the University of Wisconsin, Madison. He was a post-doctoral fellow and Assistant and Associate Professor in biochemistry and psychiatry at the Medical University of South Carolina from 1970 to 1983 where he did research on the neuropharmacology of psychotomimetic drugs, the serotonergic system, and psychopharmacology of learning and memory. He came to the NIH in 1983, first as guest researcher/pharmacologist in the National Institute of Mental Health (NIMH) intramural program working on the neuropharmacology of psychotomimetic drugs and receptor correlates of bulimia and depression followed by serving as a Scientific Review Administrator in the NIMH extramural program. He moved to the NIA in 1990 as a Health Scientist Administrator.
Contents

CTAD 2016 Program ................................................................. p. 7 - 22

Program at a glance ................................................................. p. 7 - 8

Thursday, December 8 .............................................................. p. 9 - 11

Friday, December 9 ................................................................. p. 13 - 20

Saturday, December 10 ........................................................... p. 21

Posters .................................................................................... p. 23 - 40

Sponsors ................................................................................... p. 41
### Thursday, December 8

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.45 - 8.15 a.m</td>
<td><strong>WELCOME BY THE ORGANIZING COMMITTEE</strong> and presentation of the CTAD Lifetime Achievement Award</td>
<td>Marina Ballroom DEFG - Level 3</td>
</tr>
</tbody>
</table>
| 8.15 - 8.45 a.m | **KEYNOTE 1**  
Alzheimer’s Association: Initiatives & Public Health Perspectives | San Diego Ballroom - Lobby Level              |
| 8.45 - 10.00 a.m | **ORAL COMMUNICATIONS SESSION**                                     | San Diego Ballroom - Lobby Level              |
| 10.30 - 11.30 a.m | **Symposium 1**  
Time-to-Event Endpoints for Clinical Trials in Early Alzheimer’s Disease | San Diego Ballroom - Lobby Level              |
| 11.30 - 12.00 p.m | **ORAL COMMUNICATIONS SESSION**                                     | San Diego Ballroom - Lobby Level              |
| 12.00 - 12.30 p.m | **KEYNOTE 2**  
AD Trial Design: Continuing Progress |                                             |
| 1.30 - 3.00 p.m | **ORAL COMMUNICATIONS SESSION**                                     | San Diego Ballroom - Lobby Level              |
| 3.00 - 3.30 p.m | **KEYNOTE 3**  
An Industry Perspective on Drug Development |                                             |
| 3.30 - 4.00 p.m | **ORAL COMMUNICATIONS SESSION**                                     | San Diego Ballroom - Lobby Level              |
| 4.00 - 4.30 p.m | **Coffee Break and poster sessions 1**                              | San Diego Ballroom - Lobby Level              |
| 4.30 - 5.15 p.m | **ORAL COMMUNICATIONS SESSION**                                     |                                               |
| 5.15 - 6.15 p.m | **Symposium 2**  
Non-pharmacological intervention in populations at high risk of AD dementia: results of the MAPT and LipiDiDiet studies | San Diego Ballroom - Lobby Level              |
| 7.30 - 9.00 p.m | **Welcome Reception Coronado Terrace Marriott Marina Hotel**        |                                               |
## Program at a glance

### Friday, December 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30 - 8.15 a.m</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
<td>Marina Ballroom DEFG - Level 3</td>
</tr>
<tr>
<td>8.15 - 10.00 a.m</td>
<td>Animal Models [Marina Ballroom DEF - Level 3]</td>
<td><strong>ORAL COMMUNICATIONS</strong></td>
</tr>
<tr>
<td></td>
<td>Coffee Break and poster sessions 2</td>
<td>San Diego Ballroom - Lobby Level</td>
</tr>
<tr>
<td>10.30 - 11.30 a.m</td>
<td>Symposium 3 Stem cells for Alzheimer’s disease therapeutics [Marina Ballroom DEF - Level 3]</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
</tr>
<tr>
<td>11.30 - 12.30 p.m</td>
<td><strong>ORAL COMMUNICATIONS: Parallel sessions</strong></td>
<td>Marina Ballroom DEFG - Level 3</td>
</tr>
<tr>
<td>1.30 - 2.00 p.m</td>
<td><strong>KEYNOTE 4</strong> What have we learned and what can we expect from brain imaging for Alzheimer trials</td>
<td>Marina Ballroom DEFG - Level 3</td>
</tr>
<tr>
<td>2.00 - 2.30 p.m</td>
<td><strong>PRESENTATION AND PANEL DISCUSSION</strong> Re-Evaluation of the NIA-AA Guidelines for Alzheimer’s Disease</td>
<td>Marina Ballroom DEFG - Level 3</td>
</tr>
<tr>
<td>2.30 - 3.30 p.m</td>
<td>Symposium 4 The European Prevention of Alzheimer’s Dementia (EPAD) Programme: From Readiness Cohort to Clinical Trial and the ethical framework for risk disclosure</td>
<td>Marina Ballroom DEF - Level 3</td>
</tr>
<tr>
<td></td>
<td>Coffee Break and poster sessions 2</td>
<td>San Diego Ballroom - Lobby Level</td>
</tr>
<tr>
<td>4.00 - 4.30 p.m</td>
<td><strong>PRESENTATION AND PANEL DISCUSSION</strong> ‘Subject Enrollment’ - A major barrier for developing treatments for dementia/Alzheimer’s</td>
<td>Marina Ballroom DEF - Level 3</td>
</tr>
<tr>
<td>4.30 - 6.15 p.m</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
<td>Marina Ballroom DEFG - Level 3</td>
</tr>
</tbody>
</table>

### Saturday, December 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30 - 9.00 a.m</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
<td>[Marina Ballroom DEFG - Level 3]</td>
</tr>
<tr>
<td>9.00 - 9.30 a.m</td>
<td><strong>KEYNOTE 5</strong> Alzheimer’s disease: from Proteinopathy to Prevention</td>
<td></td>
</tr>
<tr>
<td>9.30 - 10.30 a.m</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
<td></td>
</tr>
<tr>
<td>11.00 - 1.00 p.m</td>
<td><strong>Symposium 5</strong> Collaborative efforts to prevent Alzheimer’s disease</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>7.45 a.m</td>
<td><strong>Welcome by the Organizing Committee and presentation of the CtaD Lifetime Achievement Award to Dr. Neil Buckholtz</strong>&lt;br&gt;Paul Aisen, Jacques Touchon, Bruno Vellas, Mike Weiner</td>
<td></td>
</tr>
<tr>
<td>8.15 a.m</td>
<td><strong>KEYNOTE 1</strong>&lt;br&gt;Alzheimer’s Association: Initiatives &amp; Public Health Perspectives&lt;br&gt;Introduction: Jacques Touchon, Bruno Vellas&lt;br&gt;Maria Carrillo, The Alzheimer Association, Chicago, USA</td>
<td></td>
</tr>
<tr>
<td>8.45 a.m</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong>&lt;br&gt;Chairs: Maria Carrillo, Lon Schneider</td>
<td></td>
</tr>
<tr>
<td>8.45 a.m</td>
<td><strong>OC1 - Phase 3 trial of tau aggregation inhibitor therapy with LMTM in mild Alzheimer’s disease</strong>&lt;br&gt;Lon S Schneider, MD1, Serge Gauthier, MD2, Howard H Feldman, MD3, Gordon K Wilcock, MD, DSc4, Giovanni B Frisoni, MD5, Jiri Hardlund, MD6, Karin Kook, PhD7, Damon J Wischik, PhD8, Bjoern O Schelter, PhD9, John M D Storey, PhD10, Charles R Harrington, PhD11, Claude M Wischik, MD, PhD12&lt;br&gt;(1) Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, (2) McGill Centre for Studies in Aging, Verdun, Quebec, Canada, (3) University of California San Diego, CA, USA, (4) Oxford University, Oxford, UK, (5) University of Geneva, Geneva, Switzerland, (6) TauRx Therapeutics Ltd., Singapore, (7) Salamandra LLC, Bethesda, Maryland, MD, USA, (8) University of Aberdeen, Aberdeen, UK</td>
<td></td>
</tr>
<tr>
<td>9.00 a.m</td>
<td><strong>OC2 - Collaboration for Alzheimer’s Prevention: A structured approach to data and sample sharing based on CAP principles and recommendations</strong>&lt;br&gt;Maria C Carrilloα, Stacie Wenigerβ, Billy Dunnγ, Paul S Aisenδ, Randall J Batemanε, Joanne D Kotzb, Jessica B Langbaumf, Eric McDader, Susan L Mills, Eric M Reiman, Reisa Sperling, Anna M Santacruz, Pierre N Tariot, Kathleen A Welsh-Bohmer&lt;br&gt;(α) Medical &amp; Scientific Relations Division, Alzheimer’s Association, Chicago, IL, USA, (β) F-Prime Biomedical Research Initiative, Cambridge, MA, USA, (ε) Division of Neurology Products, U.S. Food and Drug Administration, Silver Spring, MD, USA, (γ) University of Southern California Alzheimer’s Therapeutic Research Institute, San Diego, CA, USA, (δ) Department of Neurology, Washington University, St Louis, MO, USA, (f) Banner Alzheimer’s Institute, Phoenix, AZ, USA, (g) Department of Neurology &amp; Psychiatry, Duke University, Durham, NC, USA</td>
<td></td>
</tr>
<tr>
<td>9.15 a.m</td>
<td><strong>OC3 - Effect of PF-06648671, a novel gamma secretase modulator, on CSF beta amyloid peptides following oral single and multiple-dose administration in healthy subjects</strong>&lt;br&gt;Ruolun Qiu, PhD1, Richann Liu, MS1, Anne-Marie Wills, MD MPH1,2,3, Fernando Dela Cruz, MS2, Charles Carriere, MS2, Ping He, MD PhD1, Eva Hajas-Kocsok, PharmD PhD1, Terrence Fullerton, PharmD2, Claire Leurent, PhD1, Robert Alexander, MD1&lt;br&gt;(1) Pfizer Inc, Neuroscience &amp; Pain Research Unit, Cambridge, MA, USA, (2) Pfizer Clinical Research Units, New Haven, CT, USA, (3) Massachusetts General Hospital, Neurology, Boston, MA, USA, (4) Pfizer Inc, Global Innovative Pharma, Cambridge, MA, USA, (5) Departments of Neurology &amp; Psychiatry, Duke University, Durham, NC, USA</td>
<td></td>
</tr>
<tr>
<td>9.30 a.m</td>
<td><strong>OC4 - Phase 3 study designs to evaluate treatment with a bace inhibitor, LY3314814/AZD3293, in patients with early alzheimer’s disease</strong>&lt;br&gt;John R Sims, MD1, Jamie A Mullen, MD2, Jennifer A Eads, PharmD1, AnnCatherine M Downing, PharmD1, Alette M Wessels, PhD1, Scott W Andersen, MS1, Jennifer A Zimmer, MD1, Katherine J Selzter, PhD1, Pierre N Tariot, MD1&lt;br&gt;(1) Eli Lilly and Company, Indianapolis, IN, USA, (2) AstraZeneca Pharmaceuticals, Cambridge, MA, USA, (3) Banner Alzheimer’s Institute, Phoenix, AZ, USA</td>
<td></td>
</tr>
<tr>
<td>9.45 a.m</td>
<td><strong>OC5 - A phase Ib, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the safety and tolerability of escalating doses of crenezumab in patients with mild-to-moderate ad</strong>&lt;br&gt;Helen Lin, MD, PhD1, Veronica Asnaghi, MD2, Michael Rabbia, MA3, Michael Ward, PhD1, Angelica Quartino, PhD1, Lee Honigberg, PhD1, Susanne Ostrowitzki, MD, PhD1, Jillian Smith2, Robert Paul, MD, PhD1, William Cho, MD, PhD1&lt;br&gt;(1) Genentech, Inc., a member of the Roche Group, South San Francisco, CA, USA, (2) F Hoffman-La Roche AG, Basel, Switzerland, (3) Roche Innovation Center, New York, NY, USA</td>
<td></td>
</tr>
<tr>
<td>10.00 a.m</td>
<td><strong>Coffee Break and poster sessions 1</strong></td>
<td></td>
</tr>
</tbody>
</table>
10.30 a.m SYMPOSIUM 1
Time-to-Event Endpoints for Clinical Trials in Early Alzheimer’s Disease
Moderator: Mary Sano, PhD, Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA

1. History of Time-to-Event in AD Clinical Trials
   Mary Sano PhD1, Barbara Schauble MD, PhD2, Robert Lasser MD, MBA2
   (1) Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA,
   (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland

2. Value of Time-to-Event in the Current Era
   José Luis Molinuevo MD, PhD1, Christin Bexelius PhD2, Susanne Ostrowitzki MD, PhD2
   (1) Scientific Director, Barcelona Beta Brain Research Centre, Pasqual Maragall Foundation, Barcelona, Spain, (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland

3. Establishing Clinical Relevance and Statistical Utility for Time-to-Event Endpoint Definitions
   Suzanne Hendrix PhD1, Howard Mackey PhD2, Chris J Edgar PhD1
   (1) Pentara Corp., Salt Lake City, Utah, USA, (2) Genentech, South San Francisco, California, USA, (3) Roche Products Limited, Welwyn Garden City, UK

11.30 a.m ORAL COMMUNICATIONS SESSION
Chairs: Pedro Pesini, Scott Turner

11.30 a.m OC6 - Resveratrol regulates neuroinflammation and induces adaptive immunity in Alzheimer’s disease
R. Scott Turner MD, PhD1, Michaeline Hebron1, Xu Huang1, Hannah Brown1, Paul Aisen MD2, Robert Rissman PhD3, Charbel Moussa MD, PhD1
   (1) Department of Neurology, Georgetown University Medical Center, Washington, D.C., USA, (2) Alzheimer’s Therapeutic Research Institute (ATRI), University of Southern California, San Diego, CA, USA, (3) Alzheimer’s Disease Cooperative Study (ADCS), University of California, San Diego, CA, USA

11.45 a.m OC7 - Results of phase I clinical trial of ABvac40, an active vaccine against Aβ40
Ana Mª Lacosta, PhD1, Pedro Pesini, PhD1, Virginia Pérez-Grijalba, PhD1, Ivan Marcos, PhD1, Leticia Sarasa, PhD1, Itziar San-José, MSc1, Laura Nuñez, BSc2, Mercé Boada, MD, PhD, Lluís Tarragó, MSc2, Agustín Ruiz, MD, PhD2, Manuel Sarasa, PhD1
   (1) Araclon Biotech, Zaragoza, Spain, (2) Grifols S.A., Barcelona, Spain, (3) Fundació ACE. Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain

12.00 p.m KEYNOTE 2
AD Trial Design: Continuing Progress
Introduction: Jacques Touchon, Bruno Vellas
Paul Aisen, Keck School of Medicine, ATRI, USC, San Diego, CA - USA

12.30 p.m Lunch Break and poster sessions

1.30 p.m ORAL COMMUNICATIONS SESSION
Chairs: Philip Scheltens, Michael Rosenblum

1.30 p.m OC8 - Optimized machine learning method for automated prescreening of patients for clinical trials
Sulantha Mathotaarachchi1, MSc, Tharick A. Pascoal1, MD, Monica Shin1, MSc, Andrea L. Benedet1, MSc, Thomas Beaudry1, BSc, Min Su Kang1, BSc, Vladimir Fonov1, PhD, Serge Gauthier1, MD, Pedro Rosa-Neto1, MD, PhD
   (1) Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada

1.45 p.m OC9 - Adaptive enrichment trial design to learn which subpopulations benefit from treatments, based on ApoE4 carrier status
Aaron Fisher, PhD1, Michael Rosenblum, PhD1
   (1) Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA

2.00 p.m OC10 - Automated Classification of Adverse Events in Clinical Studies of Alzheimer’s Disease
Gustavo A. Jimenez-Maggiore, MBA1, Rema Raman, PhD1, Karin Emstrom, MS1, Michael S.Rafii, MD, PhD1,2, Paul S.Aisen, MD1
   (1)Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego CA, 2.Department of Neurosciences, University of California, San Diego, La Jolla CA
## CTAD 2016 Program

**Thursday, December 8**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
</table>
| 2.15 p.m | **OC11** - Quantitative PET study of the effects of the p38α kinase inhibitor VX-745 on brain amyloid plaque load in patients with Early Alzheimer’s disease (AD)  
Philip Scheltens MD PhD,1, Niels Prins MD PhD,1, Adriaan A Lammertsma PhD,2, Maqsood Yaqub PhD,2, Hui-May Chu PhD,2, John Alam MD,1, Bart NM Van Berkel MD PhD1  
1. Department of Neurology and Alzheimer’s Center, VU University Medical Center, and the Alzheimers Research Center (ARC), Amsterdam, NL, 2. Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, NL, 3. Anoixis Corporation, Natick, MA, USA, EIP Pharma LLC, Cambridge, MA, USA  | Marin Ballroom DEFG - Level 3                  |
| 2.30 p.m | **OC12** - Outcomes from the Prevention of Alzheimer’s Disease with Vitamin E and Selenium trial  
Erin L. Abner, PhD1,2, Frederick A. Schmitt, PhD1,3, Richard J. Kryscio, PhD1,4  
(1) Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA, (2) Department of Epidemiology, University of Kentucky, Lexington, KY, USA, (3) Department of Neurology, University of Kentucky, Lexington, KY, USA, (4) Department of Biostatistics, University of Kentucky, Lexington, KY, USA  | Marin Ballroom DEFG - Level 3                  |
| 2.45 p.m | **OC13** - A statistical approach to centralized risk-based monitoring of AD clinical trials using an interactive open-source platform  
Rema Raman, PhD1, Gustavo Jimenez-Maggiora, MBA1, Yanxin Jiang, MS1, Michael Donohue, PhD1, Chung-Kai Sun, MS1, Karin Emstrom, MS1, Michael Rafii, MD, PhD1,4, Paul Aisen, MD1  
1. Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA, 2. Department of Neurosciences, University of California, San Diego, CA USA  | Marin Ballroom DEFG - Level 3                  |
| 3.00 p.m | **KEYNOTE 3**  
An Industry Perspective on Drug Development  
Introduction: Serge Gauthier  
David Michelson, Merck Laboratories, New Jersey, USA  | Marin Ballroom DEFG - Level 3                  |
| 3.30 p.m | **ORAL COMMUNICATIONS SESSION**  
Chairs: Susan De Santi, Guoqiao Wang  | Marin Ballroom DEFG - Level 3                  |
| 3.30 p.m | **OC14** - Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s Disease: Phase 1b/2a Update  
Roberta Diaz Brinton1, Ronald Irwin, PhD2, Kathy Rodgers, PhD1,2, Gerson Hernandez, MD2, Meng Law, MD,2, Yonggang Shi, PhD2, Dogu Aydogan, PhD2, Wendy Mack, PhD,2, Lon S. Schneider, PhD2  
1. Department of Pharmacology and Neurology, College of Medicine, University of Arizona, Tucson, AZ, USA, 2. Department of Pharmacology, School of Pharmacy, University of Southern California, 3. Department of Neuroradiology, University of Southern California, 4. UC Stevens Neuroimaging and Informatics Institute, Laboratory of Neuro Imaging (LONI), Keck School of Medicine, University of Southern California; 5. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 6. Department of Psychiatry, Keck School of Medicine, University of Southern California  | Marin Ballroom DEFG - Level 3                  |
| 3.45 p.m | **OC15** - Effect of S 47445 on functional connectivity at rest and during a task, and on glutamate concentrations in elderly subjects  
Philippe Ciuciu, PhD1, Salma Bougacha, PhD1, Fawzi Boumezbeur, PhD1, Severine Desmidt1, Chantal Ginisty1, Laurence Laurier1, Jean-Robert Deverre, PharmD, PhD1, Lucie Hertz-Pannier, MD, PhD1, Nadège Tardy, PharmD2, Maria Pueyo, MD, PhD2, Katy Bernard, PhD2  
(1) CEA/DRF/I2BM/NeuroSpin, Gif-sur-Yvette, France, (2) Pôle Innovation Thérapeutique Neuropsychiatrie, Institut de Recherches Internationales Servier, Suresnes, France  | Marin Ballroom DEFG - Level 3                  |
| 4.00 p.m | **Coffee Break and poster sessions 1**  | San Diego Ballroom - Lobby Level               |
| 4.30 p.m | **OC16** - Flurbetapir F 18 PET: from dual-phase to dual-biomarker imaging  
Sergey Scherberin, PhD1, Jennifer A. Eads, PharmD1, Adam J. Schwarz, PhD1, John R. Sims, MD1  
1. Eli Lilly & Co, Indianapolis, IN, USA, 2. Data used in preparation of this abstract were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu)  | San Diego Ballroom - Lobby Level               |
| 4.45 p.m | **OC17** - A novel disease progression model for clinical trials in dominantly inherited Alzheimer’s disease  
Guoqiao Wang, PhD1, Scott Berry, PhD2, Eric M. McCade, MD1, Chengjie Xiong, PhD1, Jason Hassenstab, MD1, Melanie Quintana, PhD2, Randall J. Bateman, MD1  
(1) The Dominantly Inherited Alzheimer Network Trials Unit, Department of Neurology, Washington University School of Medicine, St. Louis, MO  
(2) Berry Consultants, Austin, TX, USA  | San Diego Ballroom - Lobby Level               |
| 5.00 p.m | **OC18** - Optimal reference region to measure longitudinal amyloid-beta change with F-18 florbetaben PET  
Santiago Bullich1, Victor L Villenmagne2, Christopher C Rowe2, Susan De Santi1  
(1) Piramal Imaging GmbH, Berlin, Germany, (2) Department of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, VIC, Australia  
(3) Piramal Pharma Inc, Boston, MA, USA  | San Diego Ballroom - Lobby Level               |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.15-6.15p.m</td>
<td><strong>SYMPOSIUM 2</strong>&lt;br&gt;Non-pharmacological intervention in populations at high risk of AD dementia: results of the MAPT and LipiDiDiet studies&lt;br&gt;Moderators: Miia Kivipelto, MD, PhD, Karolinska Institutet, Sweden, Bruno Vellas, MD, PhD, University of Toulouse, France&lt;br&gt;1. The MAPT study: results of multi-domain intervention on cognitive performance in amyloid beta positive subjects&lt;br&gt;Sandrine Andrieu, MD, PhD, for the MAPT study group&lt;br&gt;(1) INSERM, University of Toulouse UMR1027, Toulouse, France Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France&lt;br&gt;2. LipiDiDiet Program on multi-nutrient intervention in prodromal AD: converging mechanism from preclinical and clinical results&lt;br&gt;Tobias Hartmann, PhD, for the LipiDiDiet study group&lt;br&gt;(1) Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, (2) Department of Experimental Neurology, Saarland University, Homburg, Germany&lt;br&gt;3. New results of the LipiDiDiet study: a 24-month RCT investigating the effects of Fortasyn Connect in prodromal AD&lt;br&gt;Hilkka Soininen, MD, PhD, for the LipiDiDiet study group&lt;br&gt;(1) Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland</td>
</tr>
<tr>
<td>7.00 p.m</td>
<td>Welcome Reception Coronado Terrace Marriott Marina Hotel</td>
</tr>
</tbody>
</table>
8.00 a.m

**OC21 -** Aducanumab titration dosing regimen: 12-month interim analysis from prime, a randomized, double-blind, placebo-controlled phase 1B study in patients with prodromal or mild Alzheimer’s disease

Vissia Viglietta, MD, John O’Gorman, PhD, Leslie Williams, DVM, MPH, Tianle Chen, PhD, Ahmed Enayetallah, MBCh, PhD, Ping Chiao, PhD, Christoph Hock, MD, Roger M Nitsch, MD, Samantha Budd Haeberlein, PhD, Alfred Sandrock, MD, PhD

1 Biogen, Cambridge, MA, USA, 2 Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

8.15 a.m

**ORAL COMMUNICATIONS SESSION**

**Animal Models**

**Chairs:** Jacques Hugon, Robert Rissman

**Marta Ballroom DEF - Level 3**

8.15 a.m

**OC22 -** Pre-clinical development of GMP-1, a compound that protects mitochondrial function of neurons by combating protein mis-targeting

B. Winblad, MD, PhD, A. Bernadotte, MD, PhD, G. Johansson, G. Monterro, M. Windisch, MD, PhD, P. Pavlov, PhD

1 Dept NVS, Center for Alzheimer Research, Div of Neurogeriatrics, Huddinge, Sweden, 2 Dept of Medicinal Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 3 NeuroScios GmbH, Graz, Austria, 4 Great Matter Pharma AB, Sundbyberg, Sweden

8.30 a.m

**OC24 -** Early prevention approaches targeting Aβ lowering kinase inhibition

Claire Paquet, Julien Dumurgier, François Mouton Liger, Marion Tible, Sarah Gourmaud, Jacques Hugon

Memory Center, Lanoisier Hospital Paris France, Inserm U942 Paris France Lanoisier Hospital Paris France

8.45 a.m

**OC26 -** TIO2-Nanowired cerebrolysin potentiates neuroprotective effects of anti-Tau (PHOSPHO S422) antibody in Alzheimer’s disease

1 Aruna Sharma, 2 José V.Lafuente, 3 Dafin F.Muresanu, 4 Rudy J.Castellani, 5 Mark A. Smith, 5 Ranjana Patnaik, 5 Z.Ryan Tian, 6 Asya Ozkizilcib, 7 Herbert Mössler, 7 Hari S. Sharma

1 International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, SE, 2 Dept Neurosciences, University of Basque Country, Bilbao, Spain, 3 Dept. Clinical Neurosciences, University Medicine & Pharmacy, Cluj-Napoca, Romania; a RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 4 University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 5 Case Western Reserve University Medical School, Dept. of Pathology, Cleveland, OH, USA, 6 School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of Technology, Banaras Hindu University, Varanasi, India, 7 Dept. Chemistry & Biochemistry & Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 8 Ever Neuro Pharma, Oberburgau, Austria
9.00 a.m

**ORAL COMMUNICATIONS SESSION**

**Animal Models (continued)**

Marina Ballroom DEF - Level 3

---

**OC28** - Exogenous infusion of neprilysin induces neuroprotection in Alzheimer’s Disease pathology. Potentiation with co-administration of nanowired cerebrolsynin

1Sujata Sharma, 2Jose V Lafuente, 3Dafin F Muresanu, 4Rudy J Castellani, 5Mark A Smith, 6Ranjana Patnaik, 7Ryan Tian, 8Asya Ozkizilcik, 9Herbert Mössler, 10Anita Sharma

1International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Sweden, 2Dept. of Neurosciences, University of Basque Country, Bilbao, Spain, 3Dept. of Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, 4RoNeuro Institute for Neurological Research and Diagnostic, 37 Mircea Eliade Street, 400364, Cluj-Napoca, Romania, 4University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 5Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, 6School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, 7Dept. Chemistry & Biochemistry & bBiomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 8Ever NeuroPharma, Oberburgau, Austria

---

**OC30** - Increased hippocampal vulnerability in transgenic mice overexpressing APP and triple repeat tau

Andrew Amer, BS1, Edward Rockenstein, BS1, Michael Mante, BS1, Jazmin Florio, BS1, Deborah Masilah, BS1, Anthony Adame, BS1, Eliezer Masilah, MD1, Robert A. Rissman, PhD1

1University of California, San Diego, La Jolla, CA, USA

---

**OC32** - Amyvid imaging in a murine model of Alzheimer’s Disease (AD) as a non-invasive methodology to evaluate the reduction in beta amyloid plaques after cranial irradiation

Brian Marples PhD1, Sarah A. Krueger PhD1, Daniel B. Michael MD PhD1, George D. Wilson PhD1, Alvaro A. Martinez MD1, James Fontanesi MD1

1Department of Radiation Oncology, Beaumont Health Systems, Royal Oak, MI, 2Beaumont Neurosurgery, Beaumont Health Systems, Royal Oak, MI, 3Michigan Head and Spine Institute, 21st Century Oncology of Michigan, Farmington Hills, MI, 4Department of Radiation Oncology, Beaumont Health Systems, Farmington Hills, MI

---

**ORAL COMMUNICATIONS SESSION** (continued)

Marina Ballroom G - Level 3

---

**OC29** - Serum Protein Biomarkers of δ Fully Mediate Multiple AD Conversion Risks and Offer Targets for Intervention

Donald R. Royall, MD1,4, Safa Al-Rubaye1, Ram Bisno1, Raymond F. Palmer, PhD3

1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

---

**OC31** - Aducanumab 24-month data from prime: a Randomized, double-blind, placebo-controlled phase 1B study in patients with prodromal or mild Alzheimer’s disease

Vissia Viglietta, MD1, John O’Gorman, PhD1, Leslie Williams, DVM, MPH1, Tianle Chen, PhD1, Ahmed Enayettallah, MBBC, PhD1, Ping Chiao, PhD1, Christoph Hock, MD2, Roger M Nitsch, MD2, Samantha Budd Haeberlein, PhD1, Alfred Sandrock, MD, PhD1

1Biogen, Cambridge, MA, USA, 2Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

---

**OC33** - Safety, Toleranceability and Pharmacokinetics of ABBV-8E12, a Humanized Anti-Tau Monoclonal Antibody, in a Phase 1, Single Ascending Dose, Placebo-Controlled Study In Subjects with Progressive Supranuclear Palsy

Tim West1, Joel B. Braunstein1, Ilana Fogelman1, Adam L. Boxer1, Helen Hu1, Philip B. Verghese1, Elizabeth John1, David M. Holtzman1, Randall J. Bateman1, Bradley Boevert1, Yvette M. Bondel1, Jared Brosch1, Daniel Claassen2, Jason Conner3, Erica Driver-Dunkley4, Lawrence S. Honig5, Irene Litvan6, Nick McFarland7, Erik D. Roberson8, Zbigniew K. Wszolek9, Davis Ryman10, Hana Florian10, Sandra Goss10, Diana Kerwin10

1C2N Diagnostics LLC, Saint Louis, MO, USA, 2University of California San Francisco, San Francisco, CA, USA, 3Washington University, St. Louis, MO, USA, 4Mayo Clinic Rochester, Rochester, MN, USA, 5University of California Los Angeles, Los Angeles, CA, USA, 6Indiana University, Indianapolis, IN, USA, 7Vanderbilt University, Nashville, TN, USA, 8Berry Consultants, LLC, Austin, TX, USA, 9Mayo Clinic Arizona, Scottsdale, AZ, USA, 10Columbia University, New York, NY, USA, 11University of California San Diego, San Diego, CA, USA, 12University of Florida, Gainesville, FL, USA, 13University of Alabama at Birmingham, Birmingham, AL, USA, 14Mayo Clinic Florida, Jacksonville, FL, USA, 15AbbVie Inc, North Chicago, IL, USA, 16Texas Health Presbyterian Hospital, Dallas, TX, USA
9.45  a.m  OC34 -  BACE Inhibitor CNP520 proposed for the Alzheimer's Prevention Initiative Generation Study
Ulf Neumann1, Fonda Liu2, Marie-Laure Rouzade-Dominguez1, Marie-Emmanuelle Riviere1, Mike Ufer2, Gunilla Huledal1, Nicole Pezous1, Derya Shimshek2, Carine Kolly1, Ronald G. Thomas1, Angelika Caputo1, Jessica B. Langbaum5, Pierre N. Tariot2, Eric M. Reiman4, Ana Graf3, Cristina Lopez Lopez1
(1) Novartis Institutes for Biomedical Research, Basel, Switzerland, (2) Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, (3) Novartis Pharma AG, Basel, Switzerland, (4) University of California San Diego, San Diego, USA, (5) Banner Alzheimer's Institute, Phoenix, AZ, USA

10.00  a.m  Coffee Break and poster sessions 2

10.30  a.m  SYMPOSIUM 3
Stem cells for Alzheimer’s disease therapeutics
Moderator: Lon S. Schneider, MD, Keck School of Medicine of the University of Southern California, USA

1. Stem cells for Alzheimer’s disease: Abeta amyloidosis, tau pathology and gut microbiota
Tristan Bolmont, PhD1,2, Alexei Lukashev, PhD2, Nikolai Tankovich, MD, PhD2
(1) Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland, (2) Stemmedica International, Lausanne, Switzerland and San Diego, USA

2. Clinical development for mesenchymal stem cells
Barry Baumel, MD1
(1) University of Miami, Miami, USA

3. Phase 2a trial of allogeneic human mesenchymal stem cells for Alzheimer disease
Aimee Pierce, MD, UCI, Irvine, USA

4. Discussion: Accelerating stem cell trials for Alzheimer’s disease
Lon S. Schneider, MD

10.30  a.m  ORAL COMMUNICATIONS SESSION
OC35 - Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients: Results of Medical Device Pivotal Multi-Center Study
Marwan N. Sabbagh MD 1; Alvaro Pascual-Leone; MD PhD2; Carl H. Sadowsky, MD; Babak Tousi, MD; Marc E. Agronin, MD; Gustavo Alva, MD; MD; Carmel Armon, MD; Charles Bernick, MD; Andrew P. Keegan, MD; Stella Karantzoulis, PhD
(1) Barrow Neurological Institute, Phoenix AZ USA, (2) Berenson-Allen Center for Noninvasive Brain Stimulation and Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, MA, (3) Department of Neurology, Nova SE University, Ft Lauderdale, FL, (4) Lou Ruvo Center for Brain Health Cleveland Clinic, Neurological Institute, Cleveland, OH, (5) Mental Health and Clinical Research, Miami Jewish Health Systems, Miami, FL, (6) ATP Clinical Research, Costa Mesa, CA, (7) Department of Neurology, Assaf Harofeh Medical Center, Zerifin, Israel, (8) Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, (9) Roskamp Institute Clinic, Sarasota, FL, (10) Alzheimer’s Disease Center, Center for Cognitive Neurology, New York University Langone Medical Center, New York, NY

10.45  a.m  OC36 - Predicting Onset and Spatiotemporal Spread of AD Tau Pathology using Graph Diffusion Modeling on Intrinsic Structural Brain Networks
Duygu Tosun, PhD1,2, Roksana Sadeghi, MS2, Ashish Raj, PhD, and Michael Weiner1,2, MD, for the Alzheimer’s Disease Neuroimaging Initiative
(1) Department of Radiology, University of California - San Francisco, CA, USA, (2) Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA, (3) Computer Science in Radiology, Weill Cornell Medical College, New York City, NY, USA

10.45  a.m  OC37 - Early- and late-onset Alzheimer’s disease show distinct tau pathology as examined with 18F-AV-1451 tau positron emission tomography
Michael Schöll1,2, Philip Insel1,2, Olof Strandberg1, Niklas Mattsson1, Thomas Ollsson, PhD; Douglas Hägerström1, Jonas Jögi1, Ruben Smith3, Oskar Hansson1,2
(1) Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Sweden, 2 MedTech West and the University of Gothenburg, Division of Clinical Neuroscience, Gothenburg, Sweden, 3 Skåne University Hospital, Department of Neurology, Lund, Sweden, 4 Skåne University Hospital, Department of Clinical Neurophysiology, Lund, Sweden, 5 Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden, 6 Skåne University Hospital, Department of Neuroradiology, Lund, Sweden
Friday, December 9

10.30 a.m  SYMPOSIUM 3  
Stem cells for Alzheimer’s disease therapeutics  
(continued)  
Marina Ballroom DEF - Level 3

11.00 a.m  ORAL COMMUNICATIONS SESSION  
(continued)  
Marina Ballroom G - Level 3

11.30 a.m  ORAL COMMUNICATIONS SESSION  
Chairs: Marco Bozzali, Michael Rafii  
Marina Ballroom DEF - Level 3

11.30 a.m  OC40  -  Tau PET imaging in Alzheimer’s disease and other tauopathies  
Ruben Smith1, Tomas Ohlsson2, Michael Schöll3, Martin Schain3, Andreas Hahn4, Olof Strandberg5, Jonas Jögi6, Oskar Hansson7,  
1 Department of Neurology, Skåne University Hospital, Lund, Sweden, 2 Department of Radiation Physics, Skåne University Hospital, Lund, Sweden, 3 Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden, 4 Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, 5 Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden, 6 Memory Clinic, Skåne University Hospital, Malmö, Sweden

11.15 a.m  OC39  -  Cognitive Improvement in Mild to Moderate Alzheimer’s Patients: Preliminary Results of an Open Label, Phase 2A Study of T3D-959  
John Didsbury, PhD1; Suzanne de la Monte, MD2  
(1) T3D Therapeutics, Inc., Research Triangle Park, NC, USA, (2) Neurology Department, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA

11.15 a.m  OC38  -  NILVAD: A European multicentre double-blind controlled phase III trial of Nilvadipine in mild to moderate Alzheimer’s disease  
Brian Lawlor1, Sean Kennelly1, Sarah O'Dwyer1, Fiona Cregg2, Cathal Walsh2, Robert Coen1, Rose Anne Kenny1, Robert Howard3, Caroline Murphy4, Jessica Adams5, Leslie Daly6, Ricardo Segurado7, Siobhan Gaynor8, Fiona Crawford6, Michael Mullani8, Ugo Lucca9, Florence Pasquier10, Laetitia Breuilih10, Matthias Riepe10, Janos Kalman10, Anders Wallin11, Anne Botjesson11, William Molloy12, Magda Tsolaki13, Marcel Olde Rikker14  
1 Mercer’s Institute for Research on Ageing, St. James’s Hospital, Dublin, Ireland, 2 Trinity College Dublin (TCD), Dublin, Ireland, 3 King’s College London (KCL), London, UK, 4 University College Dublin (UCD), Dublin, Ireland, 5 Molecular Medicine Ireland (MMI), Dublin, Ireland, 6 Archer Pharmaceuticals Inc, 2040 Whitefield Avenue, Sarasota, Florida, USA, 7 IRCCS—Istituto di Ricerche Farmacologiche “Mario Negri” (IRFMN), Milan, Italy, 8 Centre Hospitalier Regional et Universitaire de Lille (CHRU- LILLE), Lille, France, 9 Universitaet Ulm, (UULM), Ulm, Germany, 10 Szegedi Tudomanyegyetem (SEZGED), Szeged, Hungary, 11 Göteborgs Universitet (UGOT), Gothenburg, Sweden, 12 University College Cork (UCC), Cork, Ireland, 13 Aristotle University of Thessaloniki (AUTH), Greece, 14 Radboud Alzheimer Centre; Radboud University Medical Centre, Nijmegen, The Netherlands

11.30 a.m  OC41  -  Regions of initial amyloid-ß accumulation in Alzheimer’s disease  
Sebastian Palmqvist, MD, PhD1, Michael Schöll PhD1,2,3, Olof Strandberg PhD0, Niklas Mattsson MD, PhD0, Erik Storlud MD, PhD0, the Alzheimer’s Disease Neuroimaging Initiative, the Swedish BioFINDER study, William Jagust, MD, PhD0, Susan Landau MD, PhD0, Oskar Hansson MD, PhD0  
1Lund University, Faculty of Medicine, Department of Clinical Sciences in Malmö, Clinical Memory Research Unit, Lund, Sweden, 2Gothenburg University, MedTech West and the Department of Clinical Neuroscience, Gothenburg, Sweden, 3University of California, Berkeley, Helen Wills Neuroscience Institute, Berkeley, California, USA
### ORAL COMMUNICATIONS SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Talk Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
</table>
| 11.45 a.m | **OC42 - PET Imaging of Tau Deposition in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)**  
Michael S. Rafii, MD, PhD¹, Ansa S. Lukic, PhD², Randolph D. Andrews¹, MD, Robert A. Rissman², PhD, James B. Brewer², MD, PhD, William C. Mobley, MD, PhD³, Seth Ness, MD, PhD⁴, Dawn C. Matthews, MS⁵  1 Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego CA, 2 Department of Neurosciences, University of California, San Diego, La Jolla CA, 3 ADM Diagnostics, LLC, Chicago, IL, 4 Janssen Research and Development, LLC, Titusville, NJ |                                                                                                                                                        |
| 12.00 p.m | **OC44 - The neurobiological substrates of dynamic cognitive reserve**  
Laura Serra PhD¹, Michela Bruschini PhD¹, Camillo Marra MD², Carlo Caltagirone MD³,4, Mara Cercignani PhD⁴, Marco Bozzali MD³  1Neuroimaging Laboratory, Santa Lucia Foundation, IRCCS, Rome, Italy, 2 Institute of Neurology, Catholic University, Rome, Italy, 3Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, IRCCS, Rome, Italy, 4Department of Neuroscience, University of Rome Tor Vergata, Rome, Italy, 5Brighton & Sussex Medical School, CISC, University of Sussex, Brighton, Falmer, UK |                                                                                                                                                        |
| 12.15 p.m | **OC46 - An Assessment of Dependence Level Progression Using A Conversion Algorithm of ACDS-ADL to Dependence Scale and Data From a Double Blind Placebo Controlled Trial of Intepirdine (RVT-101)**  
Ebenezer Asare, MD¹; Carolyn Zhu PhD²; Yaakov Stern PhD³; Lawrence Friedhoff, MD PhD¹  1Axovant Sciences NY, NY, NY, (2) Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, NY, NY, (3) Cognitive Neuroscience Division, Department of Neurology and Taub Institute, Columbia University College of physicians and Surgeons NY, NY |                                                                                                                                                        |
| 12.30 p.m | **OC47 - Validation of ADFlag®, a diagnostic blood-test for pre-dementia stages of Alzheimer's disease**  
Beatrice Blanc, PhD²³, Nicolas Pelletier PhD²³, Clotilde Biscarrat¹, Pauline Martinasso¹, Samantha Galluzzi, MD⁴ Moira Marizzoni PhD⁴, Jorge Jovicich PhD⁴, Jessica Shum, BS¹, Katherine Hackett, BA¹, Jaclyn Chen, BS¹, Candace Haddox, MD,² Max Lugavere, BS¹, Josefin Meléndez-Cabrero, PhD², Matthew W. Schelke, BA¹, Lu Ji Hwang,³ Cara Berkowitz, BA¹, Emily Caeser, BA¹, Alon Seifan, MD, MS,²  1Weill Cornell Medicine, New York, NY, USA, (2) Mayo Clinic, Rochester, MN, USA, (3) Alzheimer’s Prevention Clinic and Research Center, San Juan PR, USA, (4) Weill Cornell Medicine – Qatar, Doha, Qatar, (5) Nova Southeastern University, FL, USA |                                                                                                                                                        |

---

**CTAD 2016 Program**

Friday, December 9

---

**Lunch Break and poster sessions 2**
2.00 p.m

**PRESENTATION AND PANEL DISCUSSION**

Re-Evaluation of the NIA-AA Guidelines for Alzheimer’s Disease

Chairs: Maria Carillo, Mike Wiener

Clifford R. Jack, Jr, MD.1, David A. Bennett, MD.2, Kaj Blennow, MD., PhD.3, Maria C. Carrillo, PhD.4, Cerise Elliott, PhD.5, Samantha Budd Haeberlein, MD.6, David Holtzman, MD., PhD.7, William Jagust, MD.8, Frank Jessen, MD.9, Jason Karlawish, MD.10, Enchi Liu, PhD.11, Jose Luis Molinuevo, MD.12, Thomas Montine, MD.13, Creighton Phelps, PhD.14, Katherine P. Rankin, PhD.15, Christopher Rowe, MD.16, Philip Scheltans, MD.17, Eric Seimers, MD.18, Heather M. Snyder, PhD.4, Reisa Sperling, MD.18

1. Ensuring that the EPAD Readiness Cohort remains ‘fit for purpose’
   - Craig Ritchie MD, PhD1, Lisa Vermunt MD2, Alina Solomon MD, PhD3, Luc Truyen MD, PhD3, Andrew Satlin MD, PhD4, Jose Luis Molinuevo MD, PhD5, Graciela Muniz Terrera MD1
   - Brian Tom PhD1
   - (1) University of Edinburgh, Scotland; (2) VUMC, Amsterdam, Netherlands; (3) Karolinska Institute, Stockholm, Sweden; (4) Janssen, Titusville, NJ, USA (5) Eisai Pharmaceuticals, Woodcliff Lake, NJ, USA, (6) BBRC, Barcelona, Spain (7) MRC Biostatistics Unit, University of Cambridge, UK

2. The EPAD Proof of Concept Trial: A Master Protocol for Increasing Efficiency
   - Scott Berry PhD1, Shobha Dhadha PhD2, Vlad Dragalin PhD2, Mark Fitzgerald PhD3, Philip Hougaard PhD4, Melanie Quintana PhD4
   - (1) Berry Consultants Ltd, Austin, Texas, USA (2) Eisai Pharmaceuticals, Woodcliff Lake, NJ, USA (3) Janssen, Titusville, NJ, USA (4) Lundbeck, Copenhagen, Denmark

3. From parent cohort to clinical trial in EPAD; the ethics of a stepped approach to disclosure and risk communication
   - Richard Milne1, Ana Diaz2, Sonja Bemelmans PhD3, Krista Tromp4, Eline Bunnik PhD5, Dianne Gove1, Shirlene Badger PhD6, Edo Richard MD PhD2, Marianne Maman3, Maartje Schermer1, Luc Truyen MD, PhD6, Carol Brayne PhD1
   - (1) University of Cambridge, UK (2) Radboud University, Netherlands (3) Erasmus University, Netherlands (4) Alzheimers Europe, Luxembourg (5) Novartis, Bern, Switzerland (6) Janssen, Titusville, NJ, USA
# CTAD 2016 Program

**Friday, December 9**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.00 p.m.</td>
<td><strong>PRESENTATION AND PANEL DISCUSSION</strong>&lt;br&gt;&quot;Subject Enrollment&quot; – A major barrier for developing treatments for dementia/Alzheimer’s&lt;br&gt;<strong>WORKSHOP (continued)</strong>&lt;br&gt;Part II: Controlling for false positive findings among primary and key secondary outcomes: Multiple Testing Procedures&lt;br&gt;Steve Ruberg, PhD&lt;br&gt;Eli Lilly and Company, Indianapolis, IN, USA&lt;br&gt;As the AD field is exploring earlier stages of the disease in searching for an effective treatment that alters the underlying disease pathology and slows or prevents the disease progression, special considerations need to be given to the most appropriate primary and secondary endpoints in clinical trials. This in turn presents the needs to control for false positive findings (Type I errors) for label implications and the subsequent technical challenge of how to control for multiple comparisons among primary and key secondary endpoints. Various statistical methods for controlling for multiple comparisons have been established and have been implemented in many other therapeutic areas. In this short course, an overview of the multiple testing strategies will be provided including logical explanations without the math. Various approaches will be described that may be appropriate for future AD trials, such as fixed sequence approach and more flexible and visual approaches. There will be time for Q&amp;A and interactions with participants.</td>
<td>Marina Ballroom DEF - Level 3, Marina Ballroom G - Level 3</td>
</tr>
<tr>
<td>4.30 p.m.</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong>&lt;br&gt;Chairs: Susan Abushakra, Audrey Gabelle &lt;br&gt;<strong>OC48</strong> - Tramiprosate efficacy in APOE4 carriers with mild to moderate AD: sensitivity analyses by baseline severity suggest large effects in homozygous subjects with mild AD&lt;br&gt;S. Abushakra,1 J. A. Hey,1 A. Power1, P. Wang2, L. Shen2, S. Hendrix2, S. Gauthier1, B. Vellas3, A. Porsteinsson4, M. Kivipelto1, M. Tolar1&lt;br&gt;1 Alzheon Inc., Boston, MA, USA; 2 Pharmapace Inc., San Diego, CA; 3 Pentara Corporation, Salt Lake City, Utah; 4 McGill University and Montreal Neurological Institute, Montreal, Canada; 5 University of Toulouse, Toulouse, France; 6 University of Rochester, Rochester, NY; 7 Karolinska University Hospital, Stockholm, Sweden</td>
<td>Marina Ballroom DEF - Level 3</td>
</tr>
<tr>
<td>4.45 p.m.</td>
<td><strong>OC49</strong> - The effect of APOE genotype and low CSF Abeta 42 on DHA brain bioavailability in Alzheimer’s disease&lt;br&gt;Hussein N. Yassine1, Wendy J. Mack1, Joseph F. Quinn1, Karin Yurko-Mauro1, Eileen Bailey-Hall1, Paul S. Aisen1, Helena C. Chui2, Lori S. Schneider2,3,4&lt;br&gt;1Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA, 2Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA, 3Department of Neuroscience, Oregon Health and Science University, 4Clinical Research Department, DSM Nutritional products, Columbia, MD, USA, 5Alzheimer’s Therapeutic Research Institute, University of Southern California, Los Angeles, USA, 6Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, USA, 7Department of psychiatry and the behavioral sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA</td>
<td>Marina Ballroom DEF - Level 3</td>
</tr>
<tr>
<td>5.00 p.m.</td>
<td><strong>OC50</strong> - Highly specific modification of tau phosphorylation stoichiometry in AD CSF impacts T217, S199, S202 and T205 sites but not T181&lt;br&gt;Nicolas R Barthelemy, PhD1,2, Audrey Gabelle, MD, PhD3, Chihiro Sato, PhD1, Randall J. Bateman, MD1, Sylvain Lehmann, MD, PhD2&lt;br&gt;1Neurology Department, Washington University School of Medicine, St. Louis MO, USA, 2ChU Montpellier, Montpellier, France</td>
<td>Marina Ballroom DEF - Level 3</td>
</tr>
<tr>
<td>5.15 p.m.</td>
<td><strong>OC51</strong> - Individualized trajectories in pre-symptomatic and prodromal AD: subject-specific Jack curves estimated using statistical models&lt;br&gt;Robin Wolf, PhD1, Adam J. Schwarz, PhD1, Ricardo Guerrero, PhD2, Derek Hill, PhD1&lt;br&gt;1IXICO Plc, London, UK, 2Imperial College London, London, London, UK, 3Eli Lily and Company, Indianapolis, USA</td>
<td>Marina Ballroom DEF - Level 3</td>
</tr>
</tbody>
</table>

---

1. Center for Imaging of Neurodegenerative Diseases, San Francisco VAMedical Center, San Francisco, CA, USA, (2) Alzheimer’s Association, Chicago, IL, USA, (3) National Institute on Health / National Institute on Aging (NIH/NIA), Bethesda, MD, USA, (4) Biogen Corporation, Biogen, Cambridge, MA, USA, (5) National Institute of Mental Health (NIMH), Bethesda, MD, USA, (6) Editor in Chief, Alzheimer’s & Dementia, Rockville MD, USA
Friday, December 9

**ORAL COMMUNICATIONS SESSION (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.30 p.m</td>
<td><strong>OC52 - Clinical Trials in CTE – Moving Ahead</strong></td>
<td>Charles Bernick, MD, MPH, Cleveland Clinic, USA</td>
<td></td>
</tr>
<tr>
<td>5.45 p.m</td>
<td><strong>OC53 - Computerized iPad Cognitive Testing using NIH Toolbox &amp; Cogstate C3 For Use in Clinical Trials</strong></td>
<td>Dorene M. Rentz PsyD, Rachel F. Buckley PhD, Kathryn P. Sparks BA, Maria Dekhtyar BA, Courtney Martin, Julia Sherman BA, Sarah Aghjayan BA, Samantha Burnham PhD, Reisa A. Sperling, MD</td>
<td>(1) Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA, (2) Department of Neurology, Brigham and Women’s Hospital, Boston, Massachusetts, USA, (3) Harvard Medical School, Boston, Massachusetts, USA, (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia, (5) Melbourne School of Psychological Sciences, University of Melbourne, Australia, (6) Northeastern University, Boston, Massachusetts, USA, (7) Commonwealth Scientific and Industrial Research Organization, Perth, Australia</td>
</tr>
<tr>
<td>6.00 p.m</td>
<td><strong>OC54 - What is the best question? The Functional Activity Questionnaire in the Systolic Pressure reduction Intervention trial (SPRINT) and SPRINT-MIND</strong></td>
<td>Alan J. Lerner, Gordon Chelune, Carolyn Harmon-Still, Steve Rapp, Kaycee Sink, Virginia Wadley, Jeff Williamson, Nicholas Pajewski</td>
<td>1. Departments of Neurology and Medicine, Case Western Reserve University, Cleveland, OH, 2. Center for Alzheimer’s Care, Imaging and Research, University of Utah Salt Lake City, UT, 3. Department of Psychiatry, Wake Forest School of Medicine, Winston-Salem, NC, 4. Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 5. Department of Medicine, UAB School of Medicine, Birmingham, AL, 6. Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC</td>
</tr>
</tbody>
</table>
CTAD 2016 Program
Saturday, December 10

7.30 a.m ORAL COMMUNICATIONS SESSIONS Chairs: Pierre-Jean Ousset, Lynne Shintо

OC55 - 36 Weeks of Treatment with PXT-864 in Mild Alzheimer’s disease: Results from the PLEODIAL Extension Study
Jacques Touchon, MD PhD1, Pierre-Jean Ousset, MD, PhD, Florence Pasquier, MD, PhD2, Claude Guériot, MD, PhD, Philippe Robert, MD, PhD3, Sophie Auriacombe, MD, PhD4, Jean-Marc Orgogozo, MD, PhD5, Jacques Hugon, MD, PhD6, Anne-Claire Coyne, PhD8, Viviane Bertrand, PhD8, Rodolphe Hajj, PhD8, Peter Schmitt, MSc8, Mickaël Guedj, PhD8, Daniel Cohen, MD, PhD, René Goedkoop, MD8

OC56 - Unique methodology for a Phase 2 clinical trial evaluating omega-3 fatty acids for the prevention of vascular cognitive impairment
Lynne Shintо, ND, MPH1, Lisa Silbert, MD1, Hiroko Dodge, PhD1, Joseph Quinn, MD1, Ashely Bailey, MS1, Chad Murchison, MS2, Diane Howieson, PhD3, Jeffrey Kaye, MD4, Gene Bowman, MD, MPH1
1. Neurology Department, Oregon Health & Science University, Portland, OR, USA, (2) Neurology Department, University of Michigan, Ann Arbor, MI, USA, (3) Nutrition and Brain Health, Nestle Institute of Health Sciences, EPFL campus, Lausanne, Switzerland

OC57 - Prediction of conversion from mild cognitive impairment to dementia with neurally-derived blood exosome protein profile
Charisse N. Winston, PhD1, Edward J. Goetzl, MD1, Jonny Akers, PhD1, Bob S. Carter, MD1, Edward Rockenstein, PhD1, Douglas R. Galasko, MD1, Eliezer Masliah, MD1, Robert A Rissman, PhD1
(1) University of California, San Diego, La Jolla, CA, USA, (2) Jewish Home of San Francisco, San Francisco UCSF, San Francisco, CA, USA

OC58 - Outcomes of a 3-years, multicenter, randomized double-blind, placebo-controlled, phase 2 trial to assess safety and efficacy of low-dose LADOSTIGIL in patients with Mild Cognitive Impairment
Lon S. Schneider, MD1, Yona Geffen, PhD1, Reinhold Schmidt, MD1, Stefan Ropele, PhD1, Ronald G. Thomas, PhD1, Jonathan Rabinowitz, PhD5, Martha Weinstock-Rosin, PhD6
1. Keck School of Medicine of USC, Los Angeles, CA, USA, (2) Avraham Pharmaceuticals, Ltd, Yavne, Israel, (3) Medical University, Graz, Austria, (4) University of California, San Diego, CA, USA, (5) Bar Ilan University, Ramat Gan, Israel, (6) Hebrew University, Jerusalem, Israel

OC59 - Identification of Asymptomatic Individuals at Risk of Alzheimer’s Disease using Chariot-Pro Observational Substudy as a True Historical Control to Identify Risk Factors for Amyloid Pathology
Nzera Ketters1, Nandini Raghavan1, Ziad Saad2, Chi Udoh-Momoh2, Martin Cohn3, Nina Mansoor4, Michael Arighi5, Sherry Meeh6, Dolores Szemborski1, Robert Perneckzy7, Steve Einstein1, Gary Roman8 and Lefkos Middleton9
(1) Janssen Neuroscience LLC, New Jersey, USA, (2) Neuroepidemiology and Ageing research unit, Imperial College London, UK, (3) MRC Centre for Synaptic Plasticity, Bristol University, Bristol, UK

OC60 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1, Marco Cecchi, PhD1, Paul Maruff, PhD1, Kristina M Kapiak4, Christopher U Missling PhD1
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY, USA

9.00 a.m KEYNOTE 5 Alzheimer’s disease: from Proteinopathy to Prevention
Introduction: Zaven Khachaturian
Randall Bateman, Washington University School of Medicine, St. Louis, MO, USA

9.30 a.m ORAL COMMUNICATIONS SESSION Chairs: Emily Edmonds, Michael Egan

OC61 - Removal of subjects with a “false positive” diagnosis of Mild Impairment from the Alzheimer’s Disease Cooperative Study (ADCS) donepezil trial strengthens positive effects
Emily C. Edmonds, PhD1,2, M. Colin Ard, PhD1, Steven D. Edland, PhD1,4, David P. Salmon, PhD3, Douglas R. Galasko1,2,3, Mark W. Bondi, PhD1,2
(1) Department of Psychiatry, University of California, San Diego, CA, USA, (2) Veterans Affairs San Diego Healthcare System, San Diego, CA, USA, (3) Shiley-Marcos Alzheimer’s Disease Research Center, Department of Neurosciences, University of California, San Diego, CA, USA, (4) Division of Biostatistics, Department of Family and Preventative Medicine, University of California, San Diego, CA, USA

OC62 - The Montreal Cognitive Assessment (MoCA) in 8,724 SPRINT participants: Implications for use as a screening tool in clinical trials
Kayvoes M Sink, MD, MAS1,2, Gordon Chelune, PhD1, Laura Coker, PhD1, Sarah Gaussoin, MS1, Alan Lerner, MD2, Linda Nichols, PhD3, Nick M Pajewski, PhD4, Steve Rapp, PhD5, Virginia Wadley, PhD5, Jeff Williamson, MD5
1. Wake Forest School of Medicine, Winston-Salem, NC, USA 27117, 2. University of Utah, 3. Case Western Reserve, 4. VA Medical Center, Memphis, TN, 5. University of Alabama at Birmingham, USA
ORAL COMMUNICATIONS SESSION (continued)

10.00 a.m  OC63 - Effect of symptoms of depression on tau pathology in asymptomatic elderly individuals and individuals with early AD symptomology
Duygu Tosun, PhD1,2, Scott Mackin2,3, PhD, Mitzi M. Gonzales, PhD4, David Bickford5, Craig Nelson1, MD, Michael Weiner1,2, MD, for the Alzheimer’s Disease Neuroimaging Initiative
1 Department of Radiology, University of California – San Francisco, CA, USA, 2 Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA, 3 Department of Psychiatry, University of California – San Francisco, CA, USA, 4 VA Northern California Health Care System, San Francisco, CA, USA

10.15 a.m  OC64 - Baseline characteristics for participants enrolled in the phase II/III EPOCH Alzheimer’s disease trial of the Bace inhibitor verubecestat (MK-8931)
Michael Egan, MD1, Tiffini Voss, MD1, Yi Mo, PhD1, Yuki Mukai, MD1, Christine Furtek, MS1, James Kost, PhD1, Paul S Aisen, MD2, Jeffrey L. Cummings, PhD3, David Michelson, MD4
1 Merck & Co., Inc., Kenilworth, NJ, USA, 2 University of Southern California, San Diego, CA, USA, 3 Cleveland Clinic, Las Vegas, NV, USA, 4 Banner Alzheimer’s Institute, Phoenix, AZ, USA, 5 Gerontopole, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

10.30 a.m  Coffee Break and poster sessions 3

11.00 a.m  SYMPOSIUM 5
Collaborative efforts to prevent Alzheimer's disease
Under the auspices of The Embassy of France in the United States; General Consulate of Los Angeles, Office for Science & Technology

Opening Christophe Lemoine (Consul General of France in Los Angeles)
Chairs: Paul Aisen (San Diego/USA), Howard Feldman (San Diego, USA), Jacques Touchon (Montpellier/France)

1. Alzheimer preventive trial : prevention regulatory scientific advices :
   Maria Isaac (London/UK)

2. ADNI to build Alzheimer’s preventive trials :
   Mike Weiner, Philip Insel (San-Francisco/USA)

3. MAPT trials the MAPT 2 and MAPT 3 preventive trial :
   Bruno Vellas (Toulouse/France)

11.50 a.m  Panel Round Table
Chaired by : Jean Rosenbaum, Paul Aisen, Bruno Vellas with the participation of Sandrine Andrieu (Toulouse), Randy Bateman (Saint-Louis), Maria Carrillo (Chicago), Mathieu Ceccaldi (Marseille), Jean-François Dartignes (Bordeaux), Howard Feldman (San-Diego), Howard Fillit (New-York), Audrey Gabelle (Montpellier), Serge Gauthier (Montreal), Maria Isaac (London), L.Raime Fitten (Los Angeles), Reisa Sperling (Boston), Pierre Tariot (Phoenix), Mike Weiner (San-Francisco)
POSTER PRESENTATIONS

POSTER SESSION 1 : Thursday, December 8 .............................  p. 24
   P1-1 to P1-50

POSTER SESSION 2 : Friday, December 9 .................................  p. 30
   P2-1 to P2-44

POSTER SESSION 3 : Saturday, December 10 .............................  p. 35
   P3-1 to P3-41
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, December 8

THEME 1: Clinical Trials Methodology

P1-1 INNOVATIVE PHASE II STUDY DESIGN FOR STUDYING THE GLUTAMINYLCYCLASE INHIBITOR PQ912 IN EARLY ALZHEIMER’S DISEASE
Niels D. Prins, MD, PhD(1), Frank Weber, MD(2), Suzanne Bruins, MSc(3), Inge Lues, PhD(2), Philip Scheltens, MD, PhD(1)
(1) Alzheimer Centre and Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, (2) Probiodrug AG, Halle, Germany, (3) Julius Clinical, Zevist, The Netherlands

P1-2 ALZHEIMER’S PREVENTION REGISTRY: LESSONS LEARNED IN DEVELOPING A SHARED RESOURCE TO THE SCIENTIFIC COMMUNITY
Nellie High (1), Jodie Nichols (1), David Gordon (1), Trisha Walsh (1), Raj Aggarwal (2), Paul S. Aisen (3), Marilyn S. Albert (4), Meryl Comer (5), Jeffrey L. Cummings (6), Nicholas G. Dufour (2), John J. Hardy (7), Jodie Nichols (8), Irina N. Oltarsiuk (9), William J. Weiner (10), Michael W. Weiner (11), Eric M. Reiman (1), Pierre N. Tariot (1), Jessica B. Langbaum (1)
(1) Banner Alzheimer’s Institute, Phoenix, AZ, USA, (2) Provoc, Washington, DC, USA, (3) Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA, (4) Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, (5) National Institute on Aging, Bethesda, MD, USA, (6) Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA, (7) Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA, (8) Department of Neurology, Mayo Clinic, Rochester, MN, USA, (9) Department of Neurology, Harvard Medical School, Boston, MA, USA, (10) Alzforum, Cambridge, MA, USA, (11) Department of Radiology and Biomedical Engineering, University of California San Francisco, San Francisco, CA, USA

P1-3 AGE INCREASES RATE OF Aß AND ε4 RELATED MEMORY DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE
Paul Maruff [1,2], Yen Ying Lim [2], Peter Snyder [3], Victor Villemagne [2,4], Chris Rowe [2,4], Colin Masters [2]

P1-4 PHASE 3 CLINICAL TRIAL IN MCI DUE TO AD TARGETING HIPPOCAMPAL HYPERACTIVITY
Richard Mohs (1), Sharon Rosenzweig-Lipson (1), Marilyn Albert (2), Michela Gallagher (1,3)
(1) AgeneBio, Inc. Baltimore, MD USA, (2) Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD USA, (3) Department of Psychological and Brain Sciences, Johns Hopkins University, Baltimore, MD USA

P1-5 PRIMARY PREVENTION TRIALS IN DOMINANTLY INHERITED ALZHEIMER’S DISEASE: CONSIDERATIONS IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT
Eric Mckadie, DO (1), Guoqiao Wang, PhD (2), Tammie Benzinger, MD, PhD (3), Anne Fagan, PhD (1), Jason Hassenstab, PhD (1), Chengjie Xiong, PhD (2), Randall J. Bateman, MD (1)
(1) Washington University School of Medicine at St. Louis (1) Department of Neurology, (2) Department of Medicine, Division of Biostatistics, (3) Department of Radiology

P1-6 IMPROVING PRECISION AND POWER BY ADJUSTING FOR PROGNOSTIC BASELINE VARIABLES IN ALZHEIMER’S DISEASE CLINICAL TRIALS
Michael Rosenblum, PhD (1), Elizabeth Colantuoni, PhD (1), Jon Steinbrinksson, PhD (1), Arnold Bakker, PhD (2), Michela Gallagher, PhD (3,4)
(1) Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA, (2) Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical School, Baltimore, MD USA, (3) Department of Psychological and Brain Sciences, Johns Hopkins University, Baltimore, MD USA

P1-7 SENSITIVITY OF TRIAL PERFORMANCE TO DELAYED OUTCOMES, ACCRUAL RATES, AND PROGNOSTIC VARIABLES BASED ON A SIMULATED RANDOMIZED TRIAL WITH ADAPTIVE ENRICHMENT
Michael Rosenblum, PhD (1), Tianchen Qian (PhD candidate) (1), Elizabeth Colantuoni, PhD (1), Aaron Fisher, PhD (1)
(1) Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA

P1-8 EFFECTS OF POTENTIALLY SELECTIVE END OF FOLLOW-UP IN A POPULATION WITH LATE MILD COGNITIVE IMPAIRMENT USING A DISEASE SIMULATION
Anurag Kanani, PhD (1), Ali Tafazzoli, PhD (1), Stanimir Krotneva, MSc (2), Rodrigo Dos Santos, BA (1), Jack Ishak, PhD (2)
(1) Evidera, Bethesda, MD, USA, (2) Evidera, Montreal, QC Canada

P1-9 SAMPLE SIZE CONSIDERATIONS FOR ASSESSING AGREEMENT AMONG MULTIPLE Raters IN A STUDY WITH AMNESTIC MILD COGNITIVE IMPAIRMENT
Ying Zhang, PhD (1), James Kost, PhD (1), Michael Egan, MD (1)
(1) Merck Sharp and Dohme, Upper Gwynedd, PA, USA

P1-10 THE INCREMENTAL VALIDITY OF SHORT-TERM PRACTICE EFFECTS IN DETERMINING AMYLOID POSITIVITY
Bonnie C.A. Dalley (1), Kayla R. Suhrie (1), Taylor J. Atkinson (1), Britney Beardmore (3), Kelli Rasmussen (3), Lance Burrell (3), Dustin B. Hammers (1,2), Norman L. Foster (1,2), Kevin Horn (3), Kelli Rasmussen (3), Lance Burrell (3), Dustin B. Hammers (1,2), Norman L. Foster (1,2), Kevin Duff (1,2), John M. Hoffman (3)
(1) Center for Alzheimer’s Care, Imaging and Research, Department of Neurology, University of Utah, (2) Center on Aging, University of Utah, (3) Center for Quantitative Cancer Imaging, Huntsman Cancer Institute
POSTER SESSION 1: Thursday, December 8

THEME 1: Clinical Trials Methodology (continued)

P1-11 THE ALZHEIMER’S PREVENTION REGISTRY GENEMATCH PROGRAM
Trisha Walsh (1), David Gordon (1), Jason Karlawish (2), Angela Bradbury (2), Beth McCarty Wood (2), J. Scott Roberts (3), Scott Kim (4), Linda Patrick-Miller (5), Richard J. Caselli (7), Doris Zallen (8), Carolyn Langlois (1), Eric M. Reiman (1), Pierre N. Tariot (1), Jessica B. Langbaum (1*)
(1) Banner Alzheimer’s Institute, Phoenix, AZ, (2) University of Pennsylvania, Philadelphia, PA, (3) University of Michigan, School of Public Health, Ann Arbor, MI, (4) National Institutes of Health, Bethesda, MD, (5) University of Chicago, Chicago, IL, (6) Mayo Clinic Arizona, Scottsdale, AZ, (7) Arizona State University, Tempe, AZ, (8) Virginia Tech University, Blacksburg, VA

P1-12 RISK-BENEFIT PREFERENCES FOR DELAYING THE ONSET OF ALZHEIMER’S DISEASE IN HEALTHY, ASYMPTOMATIC OLDER ADULTS
Rachael L. DiSantostefano, MS, PhD (1), Shelby D. Reed, PhD (2), Ju-Chen Yang, MEM (2), Bennett Levitan, MD, PhD (1), Johannes Streffer, MD (3), F. Reed Johnson, PhD (2)
(1) Janssen R&D, Titusville, NJ, USA, (2) Duke Clinical Research Institute, Duke University, Durham, NC, USA, (3) Janssen R&D, Beerse, Belgium

P1-13 ALZHEIMER’S DISEASE CLINICAL TRIALS: THE IMPACT OF DIGITAL TECHNOLOGIES
Amir Kalali, MD (1), Arshya Vahabzadeh, MD (2)
(1) Neuroscience Center of Excellence, Quintiles Inc, San Diego, CA, USA, (2) Harvard Medical School, Boston, MA, USA

P1-14 UTILIZING MOBILE CLINICAL TRIAL UNIT TO ENHANCE RECRUITMENT AND RETENTION IN CLINICAL TRIALS FOR ALZHEIMER’S DISEASE
Jill Smith, MA, CCRC; Amanda Smith, MD, Dave Morgan, PhD
Byrd Alzheimer’s Institute, University of South Florida, Tampa FL USA

P1-15 THE CHALLENGE OF EFFECTIVE MANAGEMENT FOR AN ACADEMIC INVESTIGATOR-INITIATED INTERNATIONAL MULTI-SITE CLINICAL RESEARCH IN JAPAN
Hisako Fuji, PhD (1), Hiroyuki Shimada, MD, PhD (1), Mikio Shoji, MD, PhD (2), Takeshi Ikeuchi, MD, PhD (3), Kazuhide Suzuki, MD, PhD (4), Michio Senda, MD, PhD (5), Kenji Ishii, MD (6), Hiroshi Matsuda, MD, PhD (7), Atsushi Iwata, MD, PhD (4), Ryoko Ibara, MD, PhD (4,8), John Morris, MD (8), Randall Bateman, MD (8), Yuichi Kato, PhD (1), Hiroshi Morii, PhD (1), and The DIAN Study Group
(1) Osaka City University Graduate School of Medicine, Osaka, JAPAN, (2) Hiroaki University Graduate School of Medicine, Aomori, JAPAN, (3) Brain Research Institute, Nagoya University, Nagoya, JAPAN, (4) Graduate School of Medicine, University of Tokyo, Tokyo, JAPAN, (5) Institute of Biomedical Research and Innovation, Hyogo, JAPAN, (6) Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, (7) National Center of Neurology and Psychiatry, Tokyo, JAPAN, (8) Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA

P1-16 SIMAMCI: A RANDOMIZED CONTROLLED TRIAL OF SIMVASTATIN IN AMNESTIC MCI PATIENTS FOR THE PREVENTION OF CONVERSION TO ALZHEIMER’S DEMENTIA
Brigitte Haas, PhD, Arne Klostermann, Oliver Peters, MD, Isabella Heuser, MD, PhD
Department of Psychiatry, Charité University Medicine Berlin, Berlin, Germany

P1-17 DESIGNING A CROSS-OVER RCT INVESTIGATING NABILONE AS A TREATMENT FOR AGITATION IN PATIENTS WITH MODERATE-TO-SEVERE AD
Myrun Ruthirkahan, MSc, PhD(c) (1,2), Nathan Herrmann, MD (1,3,4), Celina Liu, BScH (1,2), Eleonor H Abraham, BAH (1), Paul Verhoeven, MD, PhD (4), Alex Kiss, PhD (1), Ana C Andreazza, PhD (2), Sandra Black, MD (1), Krista Lancã‡t, PhD (1,2,3,4)
(1) Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, (2) Department of Pharmacology and Toxicology, University of Toronto, Canada, (3) Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada, (4) Department of Psychiatry, University of Toronto, Toronto, Canada

P1-18 CHARACTERISTICS OF THE ALZHEIMER’S DISEASE (AD) COHORTS IN THE EUROPEAN MEDICAL INFORMATION FRAMEWORK (EMIF)
Stephanie Vos (1), Angelika Wientzek (2), Preciosa Coloma (2), Myriam Alexander (2), Nadia Fossett (2), Isabella Bos (1), Sebastaan Engelborghs (3), Pieter Jelle Visser (4), H. Michael Arrighi (5), José L Molinuevo (6), Alberto Molinuevo (5), Andy Simmons (8), Gerald Novak (9), Mark Forrest Gordon (10)
(1) Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Alzheimer Center Limburg, Maastricht, the Netherlands, (2) Real World Data Science, F. Hoffmann-La Roche, Basel, Switzerland, (3) Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium, (4) Department of Neurology, Alzheimer Center, Neuroscience Campus, VU University Medical Center, Amsterdam, the Netherlands, (5) Janssen Research & Development, South San Francisco, CA, USA, (6) ICN Hospital Clinic i Universitari, IDIBAPS, Barcelona, Spain, (7) Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, (8) Kings College London, United Kingdom, (9) Janssen Pharmaceutical Research and Development, Titusville, NJ, USA, (10) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, December 8

P1-19 WHAT DOES IT MEAN TO BE TOLD YOU HAVE “ELEVATEDAMYLOID”? RESULTS FROM THE SOKRATES STUDY
Jessica Mozersky, PhD, Pamela Sankar, PhD, Kristin Harkins BA, Sara Hachey BS, Jason Karlawish, MD
University of Pennsylvania, Penn Memory Center / Perelman School of Medicine / Department of Medical Ethics and Health Policy, Philadelphia, PA, USA

P1-20 PHASE 2 TRIAL OF PIROMELATINE FOR MILD ALZHEIMER’S DISEASE (The ReCOGNITION Trial)
Amnon Katz, PhD (1), Anat Frydman, PhD (1), Tali Nir DVM (1), Lon S. Schneider, MD (2)
(1) Neurim Pharmaceuticals (1991) Ltd, Tel-Aviv, Israel, (2) University of Southern California Keck School of Medicine, Los Angeles, CA, USA

P1-21 MULTI-MODAL BIOMARKER COMPOSITE FOR DISEASE PROGRESSION IN AD PREVENTION TRIALS
John C.S. Breitner, MD, MPH, Jeannie M. Leoutsakos, PhD (2), Marilyn Albert PhD (3), PREVENT-AD Research Group (4), BIOCARD Research Group (3,5)
(1) Department of Psychiatry, McGill University, Montreal, QC, Canada, (2) Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA, (3) Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA, (4) Douglas Hospital Research Centre, Montreal, QC, Canada, (5) Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

P1-22 CHARACTERIZATION OF THE SCREENING POPULATION IN THE TOMMOROW STUDY
Ferenc Martenyi, MD (1), Kathleen A. Welsh-Bohmer, PhD (2), Carl Chiang, PhD (3), Brenda L. Plassman, PhD (2), Patrick Harrigan, BChE (1), Janet O’Neil, MBA (1), Grant Runyan, PhD (1), Meredith Culp, BS (1), Ryan Walter, BS (1), Michael W. Lutz, PhD (2), Eric Lai, PhD (1), Ann M. Saunders, PhD (2), Stephen Haneline, MS,(3), David Yarnall, MS (3), Deborah Yarbrough, MS, MBA (1), Craig Metz, PhD (3), Daniel K. Burns, PhD (3), Allen D. Roses, MD (3) for the TOMMOROW Study Investigators
(1) Takeda Development Center Americas, Inc., Deerfield, IL, USA, (2) Duke University Bryan ADRC, Durham, NC, USA, (3) Zinfandel Pharmaceuticals, Inc., Durham, NC, USA

P1-23 DESIGN OF PILOT STUDIES TO INFORM THE CONSTRUCTION OF COMPOSITE OUTCOME MEASURES
Steven D. Edland, PhD (1,2), M. Colin Ard, PhD (1), Weiwei Li, MS (3), Lingjing Jiang MS (2)
(1) Department of Neurosciences, University of California San Diego, La Jolla, CA, USA, (2) Division of Biostatistics, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA, (3) Department of Mathematics, University of California San Diego, La Jolla, CA, USA

THEME 3: Clinical Trials Imaging

P1-24 MICROSTRUCTURAL DAMAGE OF THE WHITE MATTER IN THE FRONTAL ASLANT TRACT ACCOUNTS FOR VISUO-SPATIAL PERFORMANCES IN PATIENTS WITH ALZHEIMER’S DISEASE
Laura Serra PhD (1), Giulia Bechi Gabrielli (1), Elisa Tuzzi (1), Barbara Spanò MD, PhD (1), Camillo Marra MD (2), Carlo Caltagirone MD (3,4), Mara Cercignani PhD (5), Marco Bozzali MD (1)
(1) Neuroimaging Laboratory, IRCCS Santa Lucia Foundation, Rome, (2) Institute of Neurology, Catholic University, Rome, (3) Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Rome, (4) Department of Neuroscience, University of Rome ‘Tor Vergata’, Rome, (5) Brighton & Sussex Medical School, Clinical Imaging Sciences Centre, University of Sussex, Brighton, United Kingdom

P1-25 EFFECTS OF PARTIAL VOLUME DIFFERENCES BETWEEN TIME POINTS ON LONGITUDINAL AMYLOID SUVR MEASUREMENTS
Gregory Klein (1), Joël Schaerer (2), Florent Roche (2), Mehul Sampat (1), Gennan Chen (1), Joyce Suhy (1)
(1) Bioclinica, Newark, CA, USA, (2) Bioclinica, Lyon, France

P1-26 IMPAIRMENT AND DECLINE ON THE COGSTATE BRIEF BATTERY IS RELATED TO AMYLOID AND HIPPOCAMPAL VOLUME IN VERY MILD DEMENTIA
Paul Manuff [1,2], Yen Ying Lim [2], Peter Snyder [3], Victor Villemagne [2,4], Chris Rowe [2,4] Colin Masters [2]

P1-27 TWO-POINT CORRELATION ANALYSIS OF ABNORMAL WHITE MATTER CHANGES AND THEIR ASSOCIATION TO AMYLOID PET RETENTION
Sepideh shokouhi, PhD (1), Hyeyon Kim (1), Harry E. Gwirtsman, MD (2)
(1) Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, (2) Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN

P1-28 THE RELATIONSHIP BETWEEN VOLUMETRIC MRI MEASURES,APOE4 AND MMSE STATUS AT BASELINE IN SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE PARTICIPATING IN THE PHASE 2-3 EPOCH TRIAL OF VERUBECESTAT (MK-8931)
Cyrille Sur, PhD (1), Yi Mo, PhD (1), James Kost, PhD (1), Tiffini Voss, MD (1), Joyce Suhy, PhD (2), Luc Bracoud PhD (2), Joonmi Oh, PhD (2), David Michelson, MD (1), Michael Egan, MD (1)
(1) Merck & Co., Inc., Kenilworth, NJ, USA, (2) Bioclinica, Newark, CA, USA
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, December 8

P1-29 INITIAL PH 1 TRIAL THAT WILL EVALUATE THE USE OF WHOLE BRAIN IRRADIATION IN THE TREATMENT OF PATIENTS WITH ALZHEIMER’S DEMENTIA (AD)

P1-30 UNCOVERING THE RELATIONSHIP BETWEEN β-AMYLOID AND GLUCOSE METABOLISM
Felix Carbonell (1), Donald G. McLaren (1), Alex P. Zijdenbos (1), Barry J. Bedell (1,2) (1) Biospective Inc., Montreal, Quebec, Canada, (2) McGill University, Montreal, Quebec, Canada

P1-31 ROBUSTNESS OF MRI-BASED VOLUMETRY FOR THE PREDICTION OF SHORT-TERM CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DEMENTIA
Oliver Peters, MD (1), Per Suppa (2,3), Brigitte Haas, PhD (1), Ralph Buchert, PhD (3), Lothar Spies, PhD (2), Isabella Heuser, MD, PhD (1) (1) Department of Psychiatry, Charité, Berlin, Germany, (2) jung diagnostics GmbH, Hamburg, Germany, (3) Department of Nuclear Medicine, Charité Berlin, Germany

P1-32 A NOVEL CONFORMATIONAL, PHOSPHO-THREONINE 231 SPECIFIC ASSAY FOR CSF PROTEIN TAU
Ann De Vos, PhD (1), Dirk Jacobs, Eng (1), Lien Van den Abbeele, MSc (1), Erik Stoops, Eng (1), Kimberley Mauroo, BSc (1), Maria Bjerke, PhD (2), Sebastiaan Engelborghs, MD, PhD (2), Hugo Vanderstichele, PhD(1), Eugeen Vanmechelen, PhD (1) (1) Adx Neurosciences NV, Technologiepark 4, 9052 Ghent, Belgium, (2) Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunye, University of Antwerp, Antwerp, Belgium, (3) Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium

P1-33 CT1812, A DRUG CANDIDATE FOR ALZHEIMER’S DISEASE, ACHIEVES PREDICTED THERAPEUTIC CONCENTRATIONS AFTER MULTIPLE DOSING IN HEALTHY HUMAN VOLUNTEERS
Susan Catalano, PhD (1), Michael Grundman, MD, MPH (1,2), Lon S Schneider, MD, MS (3), Steven DeKosky, MD (4), Jason D Lickliter, MBBS, PhD (5), Roger Morgan, MD (6), Michelle Higgin, PhD (1), Julie Pribyl (1), Kelsie Mozzoni (1), Nicholas J Izzo, PhD (1), Hank Safferstein, PhD (1) (1) Cognition Therapeutics Inc., Pittsburgh, PA, USA, (2) Global R&D Partners, LLC, San Diego, California, (3) Keck School of Medicine of USC, Los Angeles, CA, USA, (4) McKnight Brain Institute, University of Florida, Gainesville, FL, USA, (5) Nucleus Network, Melbourne, Victoria, Australia, (6) MedSurgPI, LLC Raleigh, North Carolina, USA

P1-34 CIRCULATING BRAIN-ENRICHED MICRONRNAS AS BIOMARKERS FOR ALZHEIMER’S DISEASE CLINICAL TRIALS
Kira S. Steineman (1), Vladimir G. Tsivinsky (1), Jon B. Toledo (2), Jennifer McBride (2), Elizabeth Grant (3), Anne M. Fagan (3), John Q. Trojanowski (2, Samuil R. Umanovsky (1) (1) DiamiR, LLC, Monmouth Junction, NJ, USA, (2) Center for Neurodegenerative Disease and Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA, (3) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
P1-35 MRI AND EEG BIOMARKERS TO TRACK DISEASE PROGRESSION IN AMCI PATIENTS WITH AD PATHOLOGY
Moira Marzorzi, PhD (1), Samantha Galluzzi, MD (1), Clarissa Ferrari, PhD (1), Jorge Jovicich, PhD (2), Flavio Nobili, MD (3), Jean-Philippe Ranjeva, MD (4), David Bartrés-Faz, MD (5), Ute Fiedler, MD (6), Peter Schönmisch, MD (7), Pierre Payoux, MD (8), Alberto Beltramello, MD (10), Massimo Calvo, PhD (11), Andrea Sorcielli, MD (12,13), Lucilla Parnetti, MD (14), Magda Tsolaki, MD (15), Paola Maria Rossini, MD (16,17), Pieter Jelle Visser, MD (18), Federica Fusco, PhD (19), Diego Albani, PhD (19), Gianluigi Forloni, PhD (19), Regis Bordet, MD (20), Jill Richardson, MD, PhD (21,22), Cecilia Estrella, PhD (23), Nicola Marzano, PhD (24), Claudio del Percio, PhD (24), Susanna Cordone, PhD (24), Claudio Babiloni, PhD (24), Olivier Blin, MD (25), Giovanni Battista Frisoni, MD (1,26); on behalf of the PharmaCog Consortium
(1) Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (2) Center for Mind/Brain Sciences, University of Trento, Trento, Italy; (3) Department of Neuroscience, Ophthalmology, Genetics and Mother–Child Health (DINOGM), University of Genoa, Genoa, Italy; (4) CIIC-UPCET, CHU La Timone, AP-HM, UMR CNRS-Université de la Mediterranee, Marseille, France; (5) Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain; (6) LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany; (7) University Hospital Leipzig, Leipzig, Germany; (8) INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France; (9) Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Place du Dr Baylac, Toulouse France; (10) Department of Neuroradiology, General Hospital, Verona, Italy; (11) University “G. d’Annunzio” of Chieti, Chieti, Italy; (12) IRCCS SDN, Naples, Italy; (13) University of Naples Parthenope, Naples, Italy; (14) Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy; (15) 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; (16) Dept. Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy; (17) IRCCS S.Raffaele Pisana, Rome, Italy; (18) Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, Netherlands; (19) Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche «Mario Negri», Milano, Italy; (20) Department of Pharmacology, EA1046, University of Lille Nord de France, Lille, France; (21) Neurosciences Therapeutic Area, U.K., United Kingdom; (22) GSK R&D, China-UK, U.K., United Kingdom; (23) AlzProtec Locs, France; (24) Sapienza University of Rome, Rome, Italy; (25) Pharmacy, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS UMR 7289, Marseille, France; (26) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

P1-36 STRATIFICATION OF MCI AND COGNITIVELY NORMAL INDIVIDUALS USING POLYGENIC SCORING: EVALUATION OF A NOVEL SNP (SINGLE NUCLEOTIDE POLYMORPHISM) ARRAY IN RISK ASSESSMENT
Maryam Shoai PhD (1); Richard Pither, PhD (3); Lakshmi Radhakrishnan MSc (7); Geoff Scopes PhD (7); Valentina Escott-Price, PhD (5); Simon M Laws PhD (4); Julie Davis, MSc (3); Harald Hampel, MD, PhD (2); Rik Vandenberghe (6); Isabelle Cleynen (6); Claire Bloor PhD (7); Greg Davidson PhD (8); John Hardy, PhD, DSc (1)
(1) UCL Institute of Neurology, London, United Kingdom; (2) AXA Research Fund & UPMC Chair, Paris, France; (3) The Institute for Cancer Research, London, United Kingdom; (4) AXA-UMPC Chair, Paris, France; (5) PIKE (Porto Inheritance of Kinesin Errors), University of Porto, Porto, Portugal; (6) Department of Pharmacology, EA1046, University of Lille Nord de France, Lille, France; (7) Neurosciences Therapeutic Area, U.K., United Kingdom; (22) GSK R&D, China-UK, U.K., United Kingdom; (23) AlzProtec Locs, France; (24) Sapienza University of Rome, Rome, Italy; (25) Pharmacy, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS UMR 7289, Marseille, France; (26) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

P1-37 LTP-LIKE CORTICAL PLASTICITY IS DISRUPTED IN ALZHEIMER’S DISEASE PATIENTS INDEPENDENTLY FROM AGE OF ONSET
Francesco Di Lorenzo MD (1,2), Viviana Ponzo B.Sc.(1) Sonia Bonni PhD (1) Caterina Motta, (1,2), Marco Bozzali MD PhD, (1), Carlo Callagirone MD,(1,2), Alessandro Martorana MD PhD, (2) Giacomo Koch MD PhD (1,4)
(1) Non Invasive Brain Stimulation Unit/Department of Behavioural and Clinical Neurology, Santa Lucia Foundation IRCCS, Via Ardeatina 354, 00179, Rome, Italy; (2) Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy

P1-38 APOE4 BLOOD MARKER ASSAY: A NEW NON-GENETIC METHOD TO EVALUATE ALZHEIMER’S DISEASE RISK USING CLINICAL CHEMISTRY PLATFORMS
Sergio Veiga, PhD (1), Andrés Rodríguez-Martín (1), Olga Calero, PhD (2), Luis García-Albert, PhD (3), Almudena Pérez (4), Sergio Gassó, PhD (4), Miguel Calero, PhD (5)
(1) Biocross S.L, Valladolid, Spain, (2) CiBERNED and Chronic Disease Programme, Instituto de Salud Carlos III. Madrid, Spain, (3) Chronic Disease Programme, Instituto de Salud Carlos III. Madrid, Spain, (4) Pragmatic Diagnostics S.L., Bellaterra (Cerdanyola del Vallés), Barcelona, Spain, (5) Chronic Disease Programme, CiBERNED, and CIEN Foundation-Queen Sofia Foundation, Instituto de Salud Carlos III. Madrid, Spain

P1-39 [18F]MK-6240 A NOVEL NEUROFIBRILLARY TANGLES PET TRACER: DISCOVERY AND CLINICAL EVALUATION
Cyrille Sur, PhD (1), Idriis Bennacel, PhD (1), Zhizhen Zeng, PhD (1), Taliad Koklith, PhD (1), Patricia J Miller (1), Cristian A Salinas, PhD (1), Brett M Connolly, PhD (1), Liza T Gantert (1), Hyking D Haley, (1) Holahan A Marie (1), Stacey S O’Malley (1), Mona L Purcell (1), Kenny Riffel, PhD (1), Paul J Coleman, PhD (2), Jing Li, PhD (2), Jaume Balsells-Padros, PhD (2), Aileen Soriano (3), Aimie M Ogawa (3), Serena Xu (3), Zhang Xiaoping (3), Joseph Della Rocca (2), Joel B. Schachter, PhD (4), Davide Hesk (5), Schen J David (5), Arie Struyk, MD, PhD (6), Cyrille Sur, PhD (1), Sofie Celen, PhD (7), Kim Serdons, PhD (7), Guy Borums, PhD (7), Mathieu Vandenbulcke, MD, PhD (7), Rik Vandenberghe, MD, PhD (7), Jan De Hoon, MD (7), Michel Koole, MD (7), Koen Van Laere, PhD, MD (7), Wajdi Abbas, PhD (2), Hostetler Eric, PhD (1), Jeffrey Evelhoch, PhD (1)
## POSTER SESSION 1: Thursday, December 8

### THEME 4: Clinical Trials: biomarkers including plasma (continued)

| POSTER NUMBER | POSTER TITLE                                                                                           | AUTHORS                                                                                   | AFFILIATIONS                                                                                                                                                                                                                                                                                                                                 |
|---------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|                                                                                                                                                                                                                                                                                                                                                       |
| P1-40         | TAU PATHOLOGY MEASURED BY 18F-AV1451 POSITRON EMISSION TOMOGRAPHY AND CEREBROSPINAL FLUID BIOMARKERS IN ALZHEIMER’S DISEASE | Niklas Mattsson, MD, PhD (1,2,3), Michael Schöll, PhD (1), Ruben Smith, MD, PhD (3), Olof Strandberg, PhD (1), Sebastian Palmqvist, MD, PhD (1,2,3), Philip Insel (1,4,5), Henrik Zetterberg, MD, PhD (6,7), Kaj Blienn, MD, PhD (6), Thomas Olsson, MD, PhD (8), Douglas Hägerström, MD, PhD (9), Jonas Jögi, MD, PhD (10), Lennart Minthon, MD, PhD (1,2), Oskar Hansson, MD, PhD (1,2) | (1) Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, (2) Memory Clinic, Skåne University Hospital, Sweden, (3) Department of Neurology, Skåne University Hospital, Sweden, (4) Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA, (5) Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA, (6) Clinical Neurochemistry Laboratory, University of Gothenburg, Gothenburg, Sweden, (7) UCL, London, UK, (8) Department of Radiation physics, Skåne University Hospital, Lund, Sweden, (9) Department of Clinical Neurophysiology, Skåne University Hospital, Lund, Sweden, (10) Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden |
| P1-42         | CSF MARKERS OF INFLAMMATION RELATE TO AD BIOMARKERS AND COGNITIVE PERFORMANCE IN HEALTHY ELDERLY AT RISK FOR AD | Pierre-François Meyer, MSc (1), Anne Labonté, BSc (1), Judes Poirier, PhD (1,2), John Breitner, MD, MPH (1,2), and the PREVENT-AD research Group | (1) Centre for Studies on Prevention of AD, Douglas Mental Health University Institute, Montreal, QC, Canada, (2) McGill University Faculty of Medicine, Montreal, QC, Canada |
| P1-43         | AN ELECTROENCEPHALOGRAPHIC MARKER OF CHOLINERGIC Activity IN THE LIVING HUMAN BRAIN WITH APPLICATION TO ALZHEIMER’S     | Magnus Johannsson (1), Jon Snaedal (2), Gisli Holmar Johannsson (1), Thorvell Eli Gudmundsson (2), Ivar Meyvantsson (1), Kristinn Jonsen (1) | (1) Mentis Cura ehf, Reykjavik, Iceland, (2) Memory Clinic, Geriatric Department, National University Hospital, Landakot, Reykjavik, Iceland |
| P1-44         | PERFORMANCE CHARACTERISTICS OF CANDIDATE CSF BIOMARKERS OF METABOLIC, INFLAMMATORY, AND VASCULAR CONTRIBUTIONS TO ALZHEIMER’S DISEASE | Aaron M. Koenig MD (1), Bianca Trombetta BA (2), Steven E. Arnold MD (2) | (1) Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA, (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA |
| P1-45         | COGNITIVE AND FUNCTIONAL CHANGES ASSOCIATED WITH Aß PATHOLOGY AND THE PROGRESSION TO MILD COGNITIVE IMPAIRMENT | Philip S. Insel, MS (1,2,3), Michael C. Donohue, PhD (4), R. Scott Mackin, PhD (2,5), Paul S. Aisen, MD (4), Oskar Hansson, MD, PhD (1,6), Michael W. Weiner, MD (2,3), Niklas Mattsson, MD, PhD (1,6,7) | (1) Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, (2) Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA, (3) Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA, (4) Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, (5) Department of Psychiatry, University of California, San Francisco, CA, USA, (6) Memory Clinic, Skåne University Hospital, Sweden 7Department of Neurology, Skåne University Hospital, Sweden |

### THEME 5: Clinical trials: cognitive and functional endpoints

| POSTER NUMBER | POSTER TITLE                                                                                           | AUTHORS                                                                                   | AFFILIATIONS                                                                                                                                                                                                                                                                                                                                 |
|---------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|                                                                                                                                                                                                                                                                                                                                                       |
| P1-46         | STRATEGIC MEMORY ALZHEIMERS REHABILITATION TRAINING (SMART): COGNITIVE PROTECTION AND INTERVENTION FOR AMNESTIC-TYPE MILD COGNITIVE IMPAIRMENT (MCI) | John W. DenBoer, Ph.D., SMART Brain Aging, Inc.                                            |                                                                                                                                                                                                                                                                                                                                                       |
| P1-47         | STRATEGIC MEMORY ALZHEIMERS REHABILITATION TRAINING (SMART) MEMORY PROGRAM: TEMPORARY IMPROVEMENT FOR MCI/VCI VIA SYSTEMATIC NOVEL COGNITIVE EXERCISE | John W. DenBoer, Ph.D., SMART Brain Aging, Inc.                                            |                                                                                                                                                                                                                                                                                                                                                       |
## POSTER PRESENTATIONS

### POSTER SESSION 1: Thursday, December 8

**THEME 5: Clinical trials: cognitive and functional endpoints (continued)**

<table>
<thead>
<tr>
<th>POSTER</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-48</td>
<td>NEURAL PREDICTORS OF COGNITIVE IMPROVEMENT BY THE MEMORY TRAINING BASED ON METAMEMORY CONCEPT IN OLDER ADULTS</td>
<td>Jun-Young Lee MD, PhD, (1) Soowon Park, PhD (2), Seung-Ho Ryu, MD, PhD (3), Jung-Hae Youn, PhD (4), Jong-Min Lee (5), PhD (5) (1) Department of Psychiatry, Seoul National University College of Medicine &amp; SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, (2) Department of Education, Sejong University, Seoul, Republic of Korea, (3) Department of Psychiatry, School of Medicine, Konkuk University, Konkuk University Medical Center, Seoul, Republic of Korea, (4) Yongmoon Graduate School of Counseling Psychology, Seoul, Republic of Korea, (5) Department of Biomedical Engineering, Hanyang University, Seoul, South Korea</td>
</tr>
<tr>
<td>P1-49</td>
<td>EXPANDING ON THE COGNITIVE FUNCTION INSTRUMENT FOR USE IN SECONDARY PREVENTION TRIALS</td>
<td>Rebecca E. Amariglio PhD (1,2,3), Dylan R. Kim MPH (2), Rachel F. Buckley PhD (2,3,4,5), Elizabeth C. Mormino PhD (2,3), Dorene M. Rentz PsyD (1,2,3), Reisa A. Sperling MD (1,2,3) (1) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA, (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA, (3) Harvard Medical School, Boston, MA USA, (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia, (5) Melbourne School of Psychological Science, University of Melbourne, Australia</td>
</tr>
<tr>
<td>P1-50</td>
<td>BIAS AND EQUIVALENCE IN CROSS-CULTURAL ITEM EQUIVALENCE OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITION (ADAS-COG)</td>
<td>Anzalee Khan (1,2), Ioan Stroescu (1), Alexandra Atkins (1), Rich Keefe (1,3) (1) NeuroCog Trials, (2) Nathan S. Kline Institute for Psychiatric Research, (3) Duke University</td>
</tr>
</tbody>
</table>

### POSTER SESSION 2: Friday, December 9

**THEME 2: Clinical Trials results**

<table>
<thead>
<tr>
<th>POSTER</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-1</td>
<td>A NOVEL SNP GENOTYPING ARRAY FOR ALZHEIMER’S DISEASE DETECTION AT THE PRECLINICAL STATE</td>
<td>Harald Hampel, MD, MSc, PhD (1,2); Maryam Shoai, PhD (3); Lakshmi Radhakrishnan, MSc (7); Richard Pither, PhD (4); Geoff Scopes, PhD (7); Marie-Claude Potier, PhD (1); Valentina Escott-Price, PhD (6); Simon M Laws, PhD (5); Simone Lista, PhD (2,8); Julie Davis, MSc (4); Claire Bloor, PhD (7); Bruno Dubois, MD, PhD (1); John Hardy, PhD, DSc (3) (1) Université Pierre et Marie Curie, Paris, France; (2) AXA Research Fund and UPMC Chair, Paris (3) UCL Institute of Neurology, London, United Kingdom; (4) Cytox Ltd, UK, Oxford, United Kingdom; (5) Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; (6) Cardiff University, Cardiff, United Kingdom; (7) Affymetrix UK and USA; (8) IHU-A-ICM – Paris Institute of Translational Neurosciences, Paris, France. The study is supported by the IHU-A-ICM, the Memento cohort, the Fondation Plan-Alzheimer, Pfizer and Amyvid/Lilly.</td>
</tr>
<tr>
<td>P2-2</td>
<td>A CLINICAL PRECISION MEDICINE APPROACH REDUCES ALZHEIMER’S, DEMENTIA AND VASCULAR RISK AND IMPROVES COGNITION: RESULTS FROM THE ALZHEIMER’S PREVENTION CLINIC PATIENT REGISTRY AT WEILL CORNELL MEDICINE AND NEW YORK-PRESBYTERIAN</td>
<td>Richard S. Isaacson, MD, (1), Robert Krikorian, PhD, (2), Katherine Hackett, BA,(1), Chiashin Shih, PhD,(1), Mu Ji Hwang, (3), Jaclyn L. Chen, BS, (1), Josefina Mélendez-Cabero, PhD, (4), Randy Cohen, MD, MS, (5), Mary Montgomery, RD, (6), Jessica Shum, BA,(1), Matthew W. Schelke, BA, (1), Roberta Marongiu, PhD, (1), Jeannette Hogg, RD,(1), Robert Kachko, ND,(7), Cara Berkowitz, BA (1), Emily Caesar, BS,(1), Alon Seifan, MD, MS,(6) (1) Weill Cornell Medicine, New York, NY, USA, (2) University of Cincinnati College of Medicine, Cincinnati, OH, USA, (3) Weill Cornell Medicine – Qatar, Doha, QATAR, (4) Alzheimer’s Prevention Clinical Research Center, San Juan PR, USA, (5) Mount Sinai St. Luke’s, New York, NY, USA, (6) NewYork-Presbyterian Hospital, New York, NY, USA, (7) Inner Source Health, New York, NY, USA, (8) Nova Southeastern University, FL, USA</td>
</tr>
<tr>
<td>P2-3</td>
<td>PREDICTING RESPONSE TO A SIX MONTH TREATMENT WITH GALANTAMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE BASED ON A SINGLE DOSE PHARMACOLOGICAL CHALLENGE</td>
<td>Anne Catrion Baakman, MD(1), Laura Camps Cardenal, BSc(1), Carmen Gavan, MD(2), Ovidiu Bajenaru, MD, PhD(2), Marieke de Kam, MSc(1), Evelien Lennstra, MD, PhD(3), Philip Scheltens, MD, PhD(3), Adam Cohen, MD, PhD(1), Joop van Gerven, MD, PhD(1), Geert Jan Groeneveld, MD, PhD(1) (1) Centre for Human Drug Research, Leiden, The Netherlands, (2) University Emergency Hospital, Department of Neurology, Bucharest, Romania, (3) Alzheimer Centre, VU University Medical Center, Amsterdam, The Netherlands</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

POSTER SESSION 2: Friday, December 9

P2-4  CLINICAL EXPERIENCE WITH A NOVEL AMYLOID-BETA PEPTIDE VACCINE FOR IMMUNOTHERAPY OF MILD ALZHEIMER'S DISEASE
P. N. Wang, MD(1*), M. J. Chiu, MD, PhD(2*), C. C. Huang, MD(3), C. C. Chang, MD(4), P. A. Frohna, MD, PhD(5), Y. T. Tseng, DVM(6,7), S. Lynn, PhD(6), X. D. Fang, PhD(7), C. L. Finstad, PhD(7), C. C. Yu, MD, PhD(5,6), C. Y. Wang, PhD(5,6,7)
(1) Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan; (2) Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan; (3) Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; (4) Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; (5) United Neuroscience, Inc., Hauppauge, NY, USA; (6) UBI Asia, HsinChu, Taiwan; (7) United Biomedical, Inc., Hauppauge, NY, USA *These two authors have equal contribution to this study

P2-5  INTEPIRDINE (RVT-101), A 5-HT6 RECEPTOR ANTAGONIST, AS AN ADJUNCT TO DONEPEZIL IN MILD-TO-MODERATE ALZHEIMER'S DISEASE: EFFICACY ON ACTIVITIES OF DAILY LIVING DOMAINS
Jason T. Olin, PhD(1), Ilise Lombardo, MD(1), Geetha Ramaswamy, MD(1), Lawrence Friedhoff, MD, PhD, FACP(1)
(1) Axovant Sciences, Inc., New York, NY, USA

P2-6  THE EFFICACY OF INTEPIRDINE (RVT-101), A 5-HT6 RECEPTOR ANTAGONIST, AS AN ADJUNCT TO DONEPEZIL IN ADULTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE: COMPLETER ANALYSIS OF A PHASE 2B STUDY
Geetha Ramaswamy, MD(1), Ilise Lombardo, MD(1), Jason T. Olin, PhD(1), Stephen C. Piscitelli, PharmD(2), Lawrence Friedhoff, MD, PhD, FACP(1)
(1) Axovant Sciences, Inc., New York, NY, USA, (2) Roivant Sciences, Inc., New York, NY, USA

P2-7  COMBINED NEURAL AND MESENCHYMAL STEM CELL THERAPY FOR PATIENTS WITH DEMENTIA: PRELIMINARY RESULTS OF A SAFETY PHASE I STUDY
Alexei Lukashev, PhD (1), Daniyar Djumaniyazov, MD, PhD (2), Yury Prokopenko, MD (2), Sakhipzhamal Idrhissova, MD, PhD (2), Abay Baigenzhin, MD, PhD (2), Tristan Bolmont, PhD (1)
(1) StemEdica International SA, Lausanne, Switzerland, (2) National Medical Scientific Center, Astana, Kazakhstan

P2-8  CRENEZUMAB EXPOSURE-RESPONSE ACROSS AD ENDPOINTS SUPPORTS A HIGHER DOSE FOR PHASE 3
Dan Polhamus PhD (2), James Rogers PhD (2), Robert Paul MD (1), Smita Kshirsagar PhD (1), Srikumar Sahasranaman PhD (1), Jin Y Jin PhD (1), Angelica L Quartino PhD (1)
(1) Genentech, San Francisco, CA, USA, (2) Metrum Research Group, Tariffville, CT, USA

P2-9  PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF THE NEW EXPLORATORY ALZHEIMER'S DRUG PIROMELATINE
Moshe Laudon, PhD1 Amnon Katz, PhD1, Anat Friedman, PhD1, Nava Zisapel PhD1
(1) Neurim Pharmaceuticals (1991) Ltd, Tel-Aviv, Israel

P2-10 PHASE 1 PROGRAM OF ALZ-801, A NOVEL PRO-DRUG OF TRAMIPROSATE WITH IMPROVED TOLERABILITY: SUPPORTS BRIDGING TO UPCOMING PHASE 3 PROGRAM
J.A. Hey (1), M. Versavel (1), S. Abushakra (1), A. Power (1), P.L. Kaplan (1), M. Tolar (1)
(1) Alzheon, Inc., Framingham, MA, USA

P2-11 RIVASTIGMINE AND CITALOPRAM TREATMENT FOR ALZHEIMER'S DISEASE IN EVERY DAY CLINICAL PRACTICE
Magda Tsolaki, MD,PhD (1), Krishna Prasad Pathak, PhD (2), Eleni Verikouki MS (3), Paschalis Devranis, MD (4), Chaido Zachou Messini MS (5), Konstantinos Lysitas MS (6), Tara Gaire. Msc, RN (7)
(1) Macedonia of University, Thessaloniki, Greece, (2) Department of Neurology, Aristotle University of Thessaloniki, Greece, (3) Eleni Verikouki, Aristotle University of Thessaloniki, Greece, (4) Paschalis Devranis, Aristotle University of Thessaloniki, Greece, (5) Chaido Zachou Messini, Aristotle University of Thessaloniki, Greece, (6) Konstantinos Lysitas, Aristotle University of Thessaloniki, Greece, (7) Star Hospital, Lalitpur, Nepal

P2-12 PHASE 2 TRIAL OF PIROMELATINE FOR MILD ALZHEIMER'S DISEASE (THE RECOGNITION TRIAL)
Amnon Katz, PhD (1), Anat Frydman, PhD (1), Tali Nir DVM (1), Lon S. Schneider, MD (2)
(1) Neurim Pharmaceuticals (1991) Ltd, Tel-Aviv, Israel, (2) University of Southern California Keck School of Medicine, Los Angeles, CA, USA
POSTER PRESENTATIONS

POSTER SESSION 2: Friday, December 9

THEME 2: Clinical Trials results (continued)

P2-13 MK7622, A POSITIVE ALLOSTERIC MODULATOR OF THE M1 ACETYLCHOLINE RECEPTOR, DOES NOT IMPROVE SYMPTOMS IN ALZHEIMER’S DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT TRIAL
Tiffini Voss, MD (1); Jerry Li, PhD (1); Jeffrey Cummings, MD (2); Rachelle Doody, MD, PhD (3); Martin Farlow (4), MD; Christopher Assaid, PhD (1); Samar Froman (1); Heather Leibensperger (1); Linda Snow-Adami (1); Kerry Budd McMahon (1); Michael Egan, MD; David Michelson, MD (1)
(1) Merck & Co. Inc., Kenilworth, NJ, USA, (2) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, (3) Baylor College of Medicine, Houston, TX, USA, (4) Indiana University School of Medicine, Indianapolis, IN, USA

P2-14 OPTIMAL ERYTHROCYTE OMEGA-3 FATTY ACID COMPOSITION CUT-OFF FOR PREDICTING COGNITIVE DECLINE AND/OR TREATMENT RESPONSE TO SUPPLEMENTATION: DATA FROM THE MAPT TRIAL
Nicola Coley (1), Mike Donohue (2), Rema Raman (2), Paul Aisen (2), Bruno Vellas (3), Sandrine Andrieu (2)
(1) UMR1027, Toulouse University, UPS, INSERM, CHU Toulouse, Department of Epidemiology and Public Health, Toulouse, France, (2) Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA, (3) UMR1027, Toulouse University, UPS, INSERM, CHU Toulouse, Gerontopole, Department of Geriatric Medicine, Toulouse, France

THEME 5: Clinical trials: cognitive and functional endpoints

P2-15 DIGITAL BIOMARKERS FOR CLINICAL TRIAL USE IN PRE-SYMPTOMATIC TO SYMPTOMATIC ALZHEIMER’S DISEASE AND RELATED DEMENTIAS - BUILDING THE REGULATORY SCIENCE ROADMAP
Stephen P. Arneric, PhD (1), Daniel R. Karlin, MD (2), Maurizio F. Facheris, MD (3), Jesse M. Cedarbaum, MD (4), Mark Forrest Gordon, MD, (5), Enrique Avilés (1), Derek L. Hill, PhD (6), Lynn D. Hudson, PhD (1), Volker D. Kern, PhD (1), Klaus Romero, MS, MD (1), Jane Rhodes, MBA, PhD (4), George Vandenbarg (7), Penny A. Dacks, PhD (8), Jeffrey A. Kaye, MD (9)
(1) Critical Path Institute, Tucson, AZ, USA, (2) Pfizer, Boston, MA, USA, (3) AbbVie, North Chicago, IL, USA, (4) Biogen, Cambridge, MA, USA, (5) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, (6) IXICO, London, United Kingdom, (7) USAgainstAlzheimer’s, Washington, DC, USA, (8) Alzheimer’s Drug Discovery Foundation, New York, NY, USA, (9) Oregon Health Science University, Portland, OR, USA

P2-16 EARLY- VERSUS LATE-ONSET ALZHEIMER’S DISEASE—DIFFERENCES IN FUNCTIONAL IMPAIRMENT
Carina Wattmo, RN, BSc, PhD (1), Åsa K. Wallin, MD, PhD (1)
(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

P2-17 NEUROPHYSIOLOGICAL EFFECT OF PXT864 IN MILD ALZHEIMER’S DISEASE PATIENTS
Karim Bennys (1), Peter Schmitt (2), Audrey Gabelle (1), Daniel Cohen (2), Jacques Touchon (1)
(1) Memory Research Resource Center for Alzheimer’s disease, University Hospital Montpellier, France, Montpellier, France, (2) Pharnext SAS, Issy les Moulineaux, France, Paris, France

P2-18 BIASED ESTIMATES OF COGNITIVE DECLINE RESULTING FROM VIOLATIONS OF MEASUREMENT INVARIANCE CAN BE EXPECTED, TESTED AND CORRECTED
Luca Kleineidam, MSc (1,2), Wolfgang Maier, MD (1,2), Michael Wagner, PhD (1,2)
(1) University of Bonn, Department of Psychiatry and Psychotherapy, Bonn, Germany, (2) DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany

P2-19 OLFACTORY IDENTIFICATION ABILITY CORRELATES WITH CSF TOTAL-TAU/AB1-42 IN NORMAL ELDERLY AT RISK OF AD
Marie-Elyse Lafaille-Magnan (1,2), Judges Poirier (1,2), Anne Labonté (1), David Fontaine (1), John Breitner (1,2), PREVENT-AD Research Group
(1) Centre for Studies on Prevention of AD, Douglas Mental Health University Institute; (2) McGill University, Faculty of Medicine, Montreal, QC, Canada

P2-20 ATYPICAL PRESENTATIONS OF ALZHEIMER’S DISEASE (AD) AND THEIR EFFECT ON DISEASE PROGRESSION AND SURVIVAL
Ajay Sood MD, PhD (1), Eveleen Darby (2) MS, Wenyaw Chan, PhD (3), Vallory Pavlik, PhD (2), Massman PJ, PhD (4), Rachelle Doody, MD, PhD (2)
(1) AMITA Health, Alexian Brothers Medical Center, Elk Grove Village, IL, USA, (2) Department of Neurology and Alzheimer’s Disease and Memory Disorders Center; Baylor College of Medicine, Houston, TX USA, (3) Department of Biostatistics, University of Texas Health Science Center at Houston, Houston, TX, USA, (4) Department of Psychology, University of Houston, TX USA

P2-21 DETECTION OF NEURODEVELOPMENTAL DIVERSITY IN AN ALZHEIMER PREVENTION COHORT USING A SELF-REPORT SCALE
Afon Seifag, MD, MS, (1), Richard S. Isaacson, MD, (2), Katherine Hackett, BA, (2) Chiaisin Shih, PhD, (2) Jaclyn L. Chen, BS, (2), Jessica Shum, BA, (2) Matthew W. Schelke, BA, (2), Robert Krikorian, PhD, (3), Eve LoCastro, MS, (4), Gloria Chiang, MD, (4), Linda Heier, MD, (4)
(1) Compass Health Systems / Nova Southeastern University, FL, USA, (2) Weill Cornell Medicine, New York, NY, USA, (3) University of Cincinnati College of Medicine, Cincinnati, OH, USA, (4) Weill Cornell Medicine, Department of Radiology, Imaging Data Evaluation & Analytics Lab
P2-22  VALUE OF PERFORMANCE-BASED OUTCOME ASSESSMENTS OF FUNCTION IN EARLY ALZHEIMER’S DISEASE CLINICAL TRIALS
Chris J Edgar, PhD (1); Meaghan Krohe PhD (2); Stephen Joel Coons PhD (3); on behalf of the Patient-Reported Outcome (PRO) Consortium’s Cognition Working Group
(1) Roche Products Ltd, Welwyn, UK, (2) Adelphi Values, Boston, MA, USA, (3) Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, AZ, USA

P2-23  INTELLIGENT CLINICAL INTERVIEWS FOR ALZHEIMER’S DISEASE: HOW THE ADDITION OF AUDIO REVIEWS TO ECOA SCALE ADMINISTRATION RESULTS IN IMPROVED DATA QUALITY
Todd M. Solomon, PhD, Jessica Meyer, BA and David S. Miller, MD, MA
Bracket, Wayne, PA, USA

P2-24  COULD OBJECTIVE MEASURES OF ACTIVITY AND THE STANDARDISATION OF ENDPOINTS HELP CLARIFY THE VALUE AND IMPACT OF EXERCISE IN PATIENTS WITH AD?
Marie McCarthy, Bill Byrom, Willie Muehlhausen
ICON PLC, Dublin Ireland

P2-25  WASURE-NAVI-TO FOR A BETTER DEMENTIA AND MCI PATIENT CARE
Atsushi Iwata, MD, PhD (1), Mamoru Yanagimachi (2), Hitomi Sunaga R.Ph.(3), Toji Miyagawa MD, PhD (1), Tatsuo Mano, MD, PhD (1), Kazushi Suzuki MD, PhD (1), Yasuhiko Nakamoto R.Ph.(3), Takafumi Watanabe, Rami Suzuki PhD (2), Shoji Tsuji MD, PhD (1)
(1) Department of Neurology, The University of Tokyo, Tokyo, Japan, (2) Eisai Co, Ltd, Tokyo, Japan, (3) Cocokara fine Healthcaro, Yokohama, Kanagawa, Japan

P2-26  OLFACTOR Y DEFICITS IN MCI AS PREDICTOR OF IMPROVED COGNITION ON DONEPEZIL: A PRELIMINARY STUDY
D.P. Devanand, MD (1,2), Gregory Pelton, MD (1), Cody Lentz, BS (1), Evan Chunga, BA (1), Karen Bell, MD (2), Jennifer Scodes, MS (3), Adam Carleglio, PhD (3)
(1) Division of Geriatric Psychiatry, Department of Psychiatry, New York State Psychiatric Institute and Columbia University Medical Center, (2) Department of Neurology and Taub Institute for Research on Alzheimer’s disease, Columbia University Medical Center, (3) Division of Biostatistics, Department of Psychiatry, Columbia University Medical Center

P2-27  STABILITY OF BAYESIAN COGNITIVE PROCESS PARAMETERS ACROSS WORDLIST MEMORY TASKS AND STUDY POPULATIONS
William R. Shankle, MS, (1,2,3), Junko Harai, PhD(1), Dennis Fortier, MS(1), William H. Batchelder, PhD(2), Gregory E. Alexander, MS(2), Ronald C. Petersen, MD, PhD(4)
(1) Medical Care Corporation, Newport Beach, CA, USA, (2) Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA, (3) Hoag Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA, (4) Mayo Clinic, Rochester, MN, USA

P2-28  REPETITIVE TMS OF THE DEFAULT MODE NETWORK: A RANDOMIZED, DOUBLE-BLINDED, CROSS-OVER STUDY TRIAL IN MCI PATIENTS
Giacomo Koch (1), Sonia Bonni (1), Silvia Picazio (1), Francesco Di Lorenzo (1), Viviana Ponzo (1), Maria Concetta Pellicciari (1), Elias Casula (1), Laura Serra (2), Matteo Mancini (2), Carlo Callagirone (1), Alessandro Martorana (3), Marco Bozzali (2)
(1) Non-Invasive Brain Stimulation Unit, Santa Lucia Foundation IRCCS, Rome, Italy, (2) Neuroimaging Laboratory, Santa Lucia Foundation, Rome, Italy, (3) Memory Clinic, Department of Neuroscience, Policlinico Tor Vergata, Rome, Italy

P2-29  COGNITIVE COMPOSITES FOR MILD COGNITIVE IMPAIRMENT (MCI): UTILITY OF THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS)
Noel Ellison, MS, Suzanne Hendrix, PhD (1)
(1) Pentara Corporation, Salt Lake City, USA

P2-30  COMPARING RATER PERFORMANCE WITH AUDIO-RECORDED VS. MOCK ADMINISTRATIONS OF COGNITIVE ASSESSMENTS IN AN ALZHEIMER’S DISEASE CLINICAL TRIAL
Gladys Valdez, PhD(1), Macarena Garcia-Valdecasas Colell, MA(1), Magda Perez, PhD(1), Stephen Sainati, MD(2), Manny Lazaro, MD(2), Stephen Brannan, MD(2), Dana Hilt, MD(2)
(1) inVentiv Health, Cary, NC, USA, (2) Forum Pharmaceuticals, Waltham, MA, USA

P2-31  PSYCHOMETRIC PROPERTIES OF COGNITIVE ENDPOINTS FROM THE CANTAB NEUROPSYCHOLOGICAL BATTERY IN A PRODROMAL ALZHEIMER’S DISEASE POPULATION
Rosemary Abbott, PhD(1), Chris Edgar, PhD(2), Francesca Cormack, PhD(1), Robert Lasser, MD, MBA(3), Elizabeth Ashford, BSc(2), Kenton Zavit, PhD(1)
(1) Cambridge Cognition, Cambridge, UK, (2) Roche Products Limited, Welwyn Garden City, UK, (3) Hoffmann-La Roche Ltd, Basel, Switzerland
POSTER PRESENTATIONS

POSTER SESSION 2: Friday, December 9

THEME 6: Cognitive Assessments and clinical trials (continued)

P2-32 COMBINING THE INFORMATION FROM MULTIPLE EPISODIC MEMORY TESTS TO OPERATIONALIZE THE DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT
G Novak MF(1), DS Keller PhD(2), MF Gordon MD(3), L Ford MD(1), A Leão MD(4), JLM Molinuevo MD PhD(5)
(1) Janssen R&D, Titusville, NJ, USA, (2) Pfizer, Cambridge, MA, USA, (3) Boehringer-Ingelheim, Ridgefield, CT, USA,
(4) Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, (5) ICN Hospital Clinic i Universitari, IDIBAPS, Barcelona, Spain

P2-33 VIRGIL PLATFORM HELPS IMPROVE SITE PERFORMANCE AND SIGNAL DETECTION IN AD TRIALS
Christopher Randolph, PhD(1,2), Selam Negash, PhD(1), Doug Osman, PhD(1), Peter Sorantin, PhD(1)
(1) MedAvante, Inc., Hamilton, NJ, USA, (2) Loyola University Medical Center, Maywood, IL, USA

P2-34 A COMPARISON OF AUDIO AND MANUAL REVIEW OF RATER PERFORMANCE IN AN ALZHEIMER’S DISEASE CENTRAL RATING REVIEW PROGRAM
Stephen M. Meyer, MA (1), Dawn Sikich (1), Elisa S. Conrad, MA (1), Magdalena Perez, PhD (1), Stephen M. Sainati, MD, PhD (2), E. Manny Lazaro (2), Stephen Brannan, MD (2), Dana Hilt, MD (2)
(1) inVentiv Health Rater Training Services, Cary, NC, USA, (2) FORUM Pharmaceuticals, Waltham, MA, USA

P2-35 IMPACT OF THE BDNF VAL66MET POLYMORPHISM ON LONG TERM MEMORY IN SUBJECTS WITH AGE-ASSOCIATED MEMORY IMPAIRMENT (AAMI)
Rebecca Crean, PhD (1), Philip Perera, MD (1), Jamie Reiter, PhD (1), Donald Connor, PhD (2), Gary Kay, PhD (3), Keith Wesnes, PhD (4), David Carpenter, PhD (1)
(1) Dart Neuroscience, San Diego, CA, USA, (2) Contractor, San Diego, CA, USA, (3) Cognitive Research Corporation, St. Petersburg, FL, USA, (4) Wesnes Cognition LTD, Streatham on Thames, England, UK

THEME 11: New therapies and clinical trials

P2-36 POTENTIAL OF PROTEOSTASIS-DIRECTED THERAPIES FOR ALZHEIMER’S DISEASE (AD)
John Alam MD (1,2)
(1) EIP Pharma LLC, Cambridge, MA, USA, (2) Alliance for Aging Research, Washington, DC, USA

P2-37 AMYLOID-ß OLMIGER MAY INDUCE NEURONAL IMPAIRMENT VIA DISRUPTING STRUCTURE AND LACTATE TRANSPORT OF OLIGODENDROCYTES
Zhongxiang Yao, MD, PhD (1), Mao Zhang, MS (1), Ziyi Ma, BS (2), Haochen Qin, BS (3), Jie Zhang, MS (1)
(1) Department of Physiology, Third Military Medical University, Chongqing, China, (2) Battalion 14 of Cadet Brigade, Third Military Medical University, Chongqing, China, (3) Battalion 10 of Cadet Brigade, Third Military Medical University, Chongqing, China

P2-38 DECONVOLUTION OF NASAL ABSORPTION OF RIVASTIGMINE IN HUMANS AND FUTURE CLINICAL DEVELOPMENT
Timothy Morgan, PhD
Lachesis Biosciences Pty Ltd, Warrnambool, VIC, AU

P2-39 SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME NOVEL N-METHYLENEBENZENAMINE Derivatives AS SELECTIVE ACETYCHOLINESTERASE INHIBITORS TO IMPROVE LEARNING AND MEMORY
Sushant Kumar Shrivastava, M.Pharm, Ph.D.(1), Pavan Srivastava, M.Pharm, Ph.D(1), TVR Upendra, M.Pharm (1), Prabhash Nath Tripathi, M.S.(Pharm) (1)
(1) Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi - India

P2-40 STUDY DESIGN AND RECRUITMENT IN TWO PHASE II PROOF-OF-CONCEPT CLINICAL TRIALS OF THE PDE9 INHIBITOR BI 409306 IN EARLY ALZHEIMER’S DISEASE
Glen Wunderlich, PhD(1), Clau Thamer, MD(2), Michael Roehrle(2), Miguel Garcia Jr., MS(3), Lutz Froelich, MD(4), Bruno Dubois, MD(5)
(1) Boehringer Ingelheim (Canada) Ltd., Burlington, ON, Canada, (2) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, (3) Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA, (4) Department of Geriatric Psychiatry, Central Institute of Mental Health, Mannheim, Germany, (5) Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), UPMC, Paris, France

P2-41 THE INFLUENCE OF A SHORT COGNITIVE AND MOBILITY TRAINING PROGRAM ON COGNITIVE PERFORMANCE AMONG THE “YOUNG-OLD” AND THE “OLD-OLD”
Carine Federspiel, MD(1,2,3), Elisabeth Bourkel, PhD(1), Jean-Paul Steinmetz, PhD(1,3)
(1) Centre for memory and mobility, Luxembourg, (2) Association Luxembourg Alzheimer, Luxembourg, (3) ZithaSenior, Research&Development, Luxembourg
POSTER PRESENTATIONS

POSTER SESSION 2: Friday, December 9

P2-42 PHARMACOKINETICS OF SINGLE DOSES OF BI 425809 IN CHINESE SUBJECTS: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS
Yasuhiro Tsuda (1), Regina Park, BPPharm (2), Hiroyuki Ugai (3), Michael Desch, PhD (4), Sophia Goetz, Dipl. Math.(4), Christina Schlecker, MD (5), Armin Schultz, MD, PhD (6), Karl-Heinz Liesenfeld (4), Sven Wind, PhD (4), Sun-Young A. Yum, MD (2,a), Glen Wunderlich, PhD (7), Jae-Gook Shin, MD, PhD (8)
(1) Nippon Boehringer Ingelheim Co. Ltd, Kobe, Japan, (2) Boehringer Ingelheim Corporation Ltd, Seoul, South Korea, (3) Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan, (4) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, (5) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, (6) CRS Clinical Research Services, Mannheim GmbH, Mannheim, Germany, (7) Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada, (8) Inje University Busan Paik Hospital, Busan, Korea. (a) At the time of study

P2-43 PHASE 3 EFFICACY, SAFETY, AND TOLERABILITY STUDIES OF AVP-786 (DEUTERATED (D6)-DEXTROMETHORPHAN HYDROBROMIDE PLUS QUINIDINE SULFATE) FOR THE TREATMENT OF AGITATION IN ALZHEIMER’S DISEASE (NCT02442765, NCT02442778, NCT02446132)
Jeffrey Cummings, MD, ScD (1); Sanjay Dube, MD (2,5); Paul Shin, MS (2); Thomas Megerian, MD, PhD (2); Stacy Wu, MD (2); Uyen Nguyen, BS (2); Constantine Lyketsos, MD, MHS (6)
(1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, (2) Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA, (3) Stanford University School of Medicine, Stanford, CA, USA, (4) Indiana University School of Medicine, Indianapolis, IN, USA, (5) University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, (6) Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

P2-44 PHASE 1 PROGRAM OF ALZ-801, A NOVEL PRO-DRUG OF TRAMIPROSATE WITH IMPROVED PHARMACOKINETIC PROPERTIES: BIOEQUIVALENCE STUDIES PROVIDE BRIDGING TO UPCOMING PHASE 3 PROGRAM
(1) Alzheon, Inc., Framingham, MA, USA

POSTER SESSION 3: Saturday, December 10

THEME 4: Clinical trials biomarkers including Plasma

P3-1 EVALUATION OF CROSS-SECTIONAL TAU BURDEN AND PRELIMINARY LONGITUDINAL CHANGES IN ALZHEIMER’S DISEASE SUBJECTS USING [18F]GTP1 (GENENTECH TAU PROBE 1)
Sandra Sanabria Bohorquez, PhD(1), Thomas Bengtsson, PhD(2), Jan Marik, PhD(3), Olivier Barret, PhD(4), Gilles Tamagnan, PhD(4), David Alagille, PhD(4), Gai Ayalon, PhD(5), Mike Ward, PhD(6), Danna Jennings, MD(4), John P. Seibyl, MD(4), Ken Marek, MD(4), Geoffrey A. Kerchner, MD PhD(6), Robby M Weiner, PhD(3)
(1) Clinical Imaging Group, (2) Biostats, (3) Department of Biomedical Imaging, (5) Department of Neuroscience, and (6) Early Clinical Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA, (4) Molecular NeuroImaging LLC, 60 Temple Street, New Haven, CT, 06510, USA

P3-2 CLUSTERIN IS A POTENTIAL BIOMARKER FOR LATE ONSET ALZHEIMER’S DISEASE
Jordan L. Holtzman, M.D.,Ph.D, Environmental Health Sciences, University of Minnesota, Minneapolis, MN
POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, December 10

THEME 6: Cognitive Assessments and Clinical Trials

P3-3 IMPACT OF DIABETES ON CAREGIVER STRESS IN PATIENTS WITH AD: DATA FROM THE ICTUS STUDY
Jun Li, West China Hospital, Sichuan University, Chengdu, CN

P3-4 IMPROVED DETECTION OF TREATMENT EFFECTS IN SEVERE ALZHEIMER'S DISEASE: A QUANTITATIVELY-DERIVED SIB-BASED COMPOSITE SCALE
Alireza Atri, MD, PhD (1,2), Suzanne Hendrix, PhD (3), Noel Ellison, MD (3), Mary Clare Kane, PhD (4), John Edwards, MD, MBA (5), George Grossberg, MD (6)
(1) Ray Dolby Brain Health Center, California Pacific Medical Center, San Francisco, CA, USA, (2) Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, (3) Pentara Corporation, Salt Lake City, UT, USA, (4) Prescott Medical Communications Group, Chicago, IL, USA, (5) Allergan, Jersey City, NJ, USA, (6) Saint Louis University, Saint Louis, MO, USA

P3-5 NEUROPSYCHOLOGICAL TESTS VALIDATED BY CSF-BIOMARKERS TO DISTINGUISH BETWEEN COGNITIVE DEFICITS DUE TO OR INDEPENDENT FROM AD IN PATIENTS PRESENTING WITH DEPRESSIVE SYMPTOMS
Oliver Peters, MD, Felix Menne, Manuel Fuentes, Brigitte Haas, PhD, Isabella Heuser, MD, PhD
Department of Psychiatry, Charité University Medicine Berlin, Berlin, Germany

P3-6 PRACTICE EFFECTS IN ALZHEIMER'S DISEASE PREVENTION TRIALS: PROOF OF CONCEPT FOR A COGNITIVE TEST RUN-IN
Diane M. Jacobs, PhD (1), M. Colin Ard, PhD (1), Steven D. Edland, PhD (1,2)
(1) Shiley-Marcos Alzheimer’s Disease Research Center, Department of Neurosciences, University of California, San Diego, CA, USA, (2) Division of Biostatistics, Department of Family Medicine & Public Health, University of California, San Diego, CA, USA

P3-7 IMPROVING COGNITIVE SCREENING ACCURACY AND EFFICIENCY FOR MINIMALLY IMPAIRED INDIVIDUALS
William Souillard-Mandar (1), Randall Davis, PhD (1,2), Rhoda Au, PhD (3), Dana L. Penney, PhD (1,4)
(1) Digital Cognition Technologies, Inc, Waltham, MA, USA, (2) MIT Computer Science And Artificial Intelligence Laboratory, Cambridge, MA, USA, (3) Boston University Schools of Medicine and Public Health, Boston, MA, USA, (4) Lahey Hospital and Medical Center, Burlington, MA, USA

P3-8 VALIDATION OF AN AUTOMATED SCORING METHOD FOR WEB CAMERA EYE TRACKING ON A VISUAL PAIRED COMPARISON TASK
Nicholas T. Bott, PsyD (1,2), Alex Lange, MS (2), Robert Cosgriff, MS (2), Paul Clotpton, MS (3), Beth Buffalo, PhD (2,4), Dorene M. Rentz, PsyD (5,6,7), Stuart Zola, PhD (2,8)
(1) Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA, (2) Neurotrack Technologies, Inc., Redwood City, California, USA, (3) University of California San Diego School of Medicine, San Diego, California, USA, (4) University of Washington, Seattle, Washington, USA, (5) Massachusetts General Hospital, Boston, Massachusetts, USA, (6) Harvard Medical School, Boston, Massachusetts, USA, (7) Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, (8) Emory University Office of the Provost, Atlanta, Georgia, USA

THEME 7: Behavioral disorders and clinical trials

P3-9 ASSOCIATION OF SUBSYNDROMAL SYMPTOMS OF DEPRESSION WITH COGNITIVE DECLINE AND CORTICAL ATROPHY IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT
R. Scott Mackin, Ph.D.(1,2), Philip S. Insels, MS (2), Craig Nelson, MD (1), Mitzi M. Gonzales, Ph.D. (1,3), Duygu Tosun, Ph.D.(2,4), Niklas Mattsson, MD, Ph.D. (5,6), Susanne G. Mueller, MD (2,4), Simona Sacuici, MD, Ph.D.(7), David Bickford, BA (1), Michael W. Weiner, MD (1,2,4,8), and the Alzheimer’s Disease Neuroimaging Initiative
(1) Department of Psychiatry, University of California, San Francisco, CA, USA, (2) Center for Imaging of Neurodegenerative Diseases, Veterans Administration Medical Center, San Francisco, CA, USA, (3) Department of Radiology, University of California, San Francisco, CA, USA, (4) Department of Radiology, University of California, San Francisco, CA, USA, (5) Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, (6) Department of Neurology, Skane University Hospital, Lund, Sweden, (7) Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, (8) Department of Medicine, University of California, San Francisco, CA, USA

P3-10 CHANGES IN NEUROPSYCHIATRIC SYMPTOMS OVER 3 YEARS BETWEEN EARLY –VERSUS LATE-ONSET AMNESTIC MILD COGNITIVE IMPAIRMENT
Geon Ha Kim (*a), Jong-Won Kim (*b), Youngshin Yoon (c), Kyoung-Gyu Choi (a), Seong Hye, Choi (d), Jee Hyang Jeong (a)
(1) Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea, (b) Department of Emergency Medicine, School of medicine, Konkuk University, Konkuk University Medical Center, Seoul, Republic of Korea, (c) Department of Neurology, Seoul Metropolitan Seonam Hospital, Seoul, Korea, (d) Department of Neurology, Inha University Hospital, Inha University School of Medicine, Incheon, Korea
POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, December 10

P3-11 USING ENVIRONMENTAL LIGHT THERAPY TO IMPROVE SLEEP AND NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA

Sébastien Gonfrier, MD(3), Sawasai Al Rifai, MD(1), Linda Benattar, MD(2), Laurence Merlin, MD(2), Philippe Zawieja, PhD(2), Olivier Guerin, MD, PhD(3)
(1) EHPAD Les Pastoureaux, Valenton, France, (2) ORPEA group, Puteaux, France, (3) CHU Nice, France

THEME 9: Epidemiology and clinical trials

P3-12 OPERATIONALIZING THE IWG2 AND NIA-AA DIAGNOSTIC CRITERIA IN SIX EUROPEAN COHORTS

W Tang (1), G Novak (2), MF Gordon (1), S Engelborghs (3), Stephanie J. B. Vos (4), A Lleó (5), JL Molinuevo (6), Giovanni B Frisoni (7), Pieter Jelle Visser (4,8)
(1) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, (2) Janssen Pharmaceutical Research and Development, Titusville, NJ, USA, (3) University of Antwerp, Antwerp, Belgium, (4) Maastricht University, Maastricht, the Netherlands, (5) Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, (6) ICN Hospital Clinic i Universitari, IDIBAPS, Barcelona, Spain, (7) University Hospitals and University of Geneva, Switzerland, and IRCCS Fatabenefratelli, Brescia, Italy, (8) VU University Medical Center, Amsterdam, the Netherlands

P3-13 AMYLOID PATHOLOGY IN THE PROGRESSION TO MILD COGNITIVE IMPAIRMENT

Philip Insel, MS (1,2,3), Oskar Hansson, PhD (1,5), R. Scott Mackin, PhD (2,4), Michael Weiner, MD (2,3), Niklas Mattsson, MD, PhD (1,5,6), for the Alzheimer’s Disease Neuroimaging Initiative (7)
(1) Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, (2) Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA, (3) Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA, (4) Department of Psychiatry, University of California, San Francisco, CA, USA, (5) Memory Clinic, Skåne University Hospital, Sweden, (6) Department of Neurology, Skåne University Hospital, Sweden

P3-14 UTILIZING ADMINISTRATIVE CLAIMS DATA TO IDENTIFY SEVERITY IN PATIENTS WITH ALZHEIMER’S DISEASE: CHALLENGES AND OPPORTUNITIES

Fanta W Puravidathil, PhD, MPH(1), Sarah Cadarette, MS(2), Amanda Forys, MSPH(2), Trent McLaughlin BSc(Pharm), PhD(2), Manasee Shah, MPH(2), Myrlene Sanon Aigbogun, MPH(3)

THEME 10: Animal model and clinical trials

P3-15 AMELIORATION OF GASTRO-INTESTINAL MICROBIOTA FOLLOWING STEM CELL TREATMENT IN A MOUSE MODEL OF CEREBRAL ABETA AMYLOIDOSIS

Tristan Bolmont, PhD (1,2), Taoufiq Harach (2), Alexei Lukashev, PhD (1), Nikolai Tankovich, MD, PhD (3)
(1) StemEdica International, Lausanne, Switzerland, (2) Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland, (3) StemEdica Cell Technologies, San Diego, CA, USA

P3-16 BI 425809, A NOVEL GLYT1 INHIBITOR, INCREASES GLYCINE LEVELS IN CEREBROSPINAL FLUID (CSF): RESULTS FROM PRECLINICAL AND CLINICAL TRANSLATIONAL PROOF-OF-MECHANISM STUDIES

Holger Rosenbrock, PhD (1), Viktoria Moschetti, MD (2), Oliver Kleiner, PhD (1), Michael Desch, PhD (1), Christina Schlecker, MD (2), Sophia Goetz, Dipl. Med.(1), Karl-Heinz Lienesfeld (1), Sun-Young A. Yum, MD (3,a), Gwenaëlle Fillon, PhD (1), Glen Wunderlich, PhD (4), Sven Wind, PhD (1)
(1) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, (2) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, (3) Boehringer Ingelheim Corporation Ltd, Seoul, South Korea, (4) Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada, *No longer an AstraZeneca employee

P3-17 REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293 ARE RELATED TO BACE2 INHIBITION AND CONFINED TO SKIN AND HAIR

Gvido Cebers, MD, PhD (1); Magnus Soderberg, MD, PhD (2); Evan W. Ingersoll, PhD (1); Robert C. Alexander, MD (1*); Samantha Budd Haebelerlein, PhD (1*); Alan R. Kugler PhD (1*); Bassem Attalla, BS (3); Théphaine Lejeune, DVM, DECVP (3); Stefan Platzer, DVM, PhD (2); Clay W. Scott, PhD (4)

P3-18 APP GENE DOSE MEDIATED NEURODEGENERATION IN MOUSE MODELS OF DOWN SYNDROME

Mariko Sawa, PhD (1), Cassia Overk, PhD (1), Eliezer Masliah, MD (1), Ann Becker (1), Xu Chen, PhD (1), Chengbiao Wu, PhD (1), William Mobjley, MD, PhD (1)
(1) Department of Neurosciences, University of California San Diego, San Diego, CA, USA
**THEME 10: Animal model and clinical trials (continued)**

**P3-19**  
**TRANSLATIONAL APPROACH TO NEURODEGENERATIVE DISEASES: A SMALL PEPTIDE DERIVED FROM NEURONAL CELL CYCLE KINASE (CDK5) PREVENTS NEURODEGENERATION**  
Harish C. Pant, Chief, Cytoskeletal Protein Regulation Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

**P3-20**  
**PRECLINICAL STUDIES OF SAk3, A T-TYPE CALCIUM CHANNEL STIMULATOR IN APP23 MICE AND RATS**  
Kohji Fukunaga PhD, Hisanao Izumi, Yasuharu Shinoda, Yasushi Yabuki PhD  
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan

---

**THEME 11: New therapies and clinical trials**

**P3-21**  
**SUVN-502: A PURE 5-HT6 ANTAGONIST FIRST-IN-CLASS TRIPLE COMBINATION PHASE-2 POC STUDY. A PROMISING THERAPEUTIC STRATEGY FOR SYMPTOMATIC TREATMENT OF AD**  
Ramakrishna Nirogi, PhD(1), Koteshwara Mudigonda, PhD(1), Devender Reddy Ajala, PhD(1), Vijay Benade MS(1), Renny Abraham, PhD(1), Ramaasathy Kambhampati, PhD(1), Anil Shinde, PhD(1), Venkat Jasti MS(1)  
(1) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**P3-22**  
**SUVN-G3031: A POTENT AND SELECTIVE H3 RECEPTOR INVERSE AGONIST - SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY ADULT MEN**  
Ramakrishna Nirogi, PhD(1), Koteshwara Mudigonda, PhD(1), Nageswararao Muddana, MS(1), Rajesh Kumar Boggavarapu, MS(1), Ranjith Kumar Ponnamaneni MS(1), Pradeep Jayarajan, PhD(1), Anil Shinde PhD(1), Venkat Jasti MS(1)  
(1) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**P3-23**  
**SUVN-D4010: A POTENT AND SELECTIVE 5-HT4 RECEPTOR PARTIAL AGONIST - SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY ADULT MEN**  
Ramakrishna Nirogi, PhD(1), Koteshwara Mudigonda, PhD(1), Gopinadh Bhyrapuneni, PhD(1), Veera Raghava Chowdary Palacharla, MS(1), Rajesh Kumar Boggavarapu, MS(1), Devender Reddy Ajala, PhD(1), Abdul Rasheed Mohammed, PhD(1), Venkat Jasti MS(1)  
(1) Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

**P3-24**  
**A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO TEST THE EFFICACY AND SAFETY OF S 47445 IN PATIENTS SUFFERING FROM ALZHEIMER’S DISEASE AT MILD TO MODERATE STAGE WITH DEPRESSIVE SYMPTOMS**  
Pueyo Maria, MD, PhD(1), Bernard Katy, PhD(1), Bretn Sylvie, PharmD, PhD(1), Gouttefangeas Sylvie, MD(1), Picarel-Blanchot France, PhD(1)  
Pôle Innovation Thérapeutique Neuropsychiatrie, Institut de Recherches Internationales Servier, Suresnes, France

**P3-25**  
**THROMBIN: A VASCULAR-DERIVED NEUROTOXIN AND NOVEL TARGET FOR AD THERAPY**  
Paula Grammas, PhD, George, Anne Ryan  
Institute for Neuroscience, University of Rhode Island, Kingston, RI, USA

**P3-26**  
**MULTIPLE ASCENDING DOSE STUDY WITH A PRODRUG OF GALANTAMINE: EVIDENCE OF DIMINISHED SIDE EFFECTS**  
D.G. Kay PhD(1), E’t’Hart PhD(2), C. Bakker MD (2), J. van der Aart Msc (2), G.J. Groeneveld MD PhD(2), A. Maelicke PhD (1,3)  
(1) Neurodyn Cognition Inc., Charlottetown, PE, Canada, (2) Centre for Human Drug Research (CHDR), Leiden, the Netherlands, (3) Galantos Pharma, Nieder-Olm, Germany

**P3-27**  
**NO DOSE ADJUSTMENT REQUIRED FOR E2609, A NOVEL BACE1 INHIBITOR, FOR JAPANESE SUBJECTS, BASED ON PHARMACODYNAMIC AND PHARMACOKINETIC COMPARISONS WITH WHITE COHORTS**  
Oneeb Majid, PhD(1), Michelle Gee, PhD(1), Bruce Albala, PhD(2), Peter Boyd, MSc(1), June Kaplow, PhD(2), Satish Dayal, BSc, Min-Kun Chang, PhD(2), Nozomi Hayata, MSc(3), Kenya Nakai, MSc(3), Sanae Yasuda, PhD(3), Bhalakar Rege, BPharm, PhD(2)  

**P3-28**  
**DOSE-RELATED REDUCTIONS OF CSF AMYLOID B (1-X) BY E2609, A NOVEL BACE INHIBITOR IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (AD) AND MILD-MODERATE AD DEMENTIA**  
Oneeb Majid, PhD(1), Michelle Gee, PhD(1), Bruce Albala, PhD(2), Robert Lair, MA, MB Chir, PhD(1), Satish Dayal, BSc, Min-Kun Chang, PhD(2), Nozomi Hayata, MSc(3), Kenya Nakai, MSc(3), Sanoe Yasuda, PhD(3), Bhaskar Rege, BPharm, PhD(2)  
(1) Eisai Co. Ltd., London, UK, (2) Eisai Inc., Woodcliff Lake, NJ, USA

**P3-29**  
**ADVANCING THERAPEUTICS FOR NEUROINFLAMMATION IN ALZHEIMER’S DISEASE: CLINICAL DEVELOPMENT CONSIDERATIONS**  
Richard Margolin MD(1), Lon Schneider MD, MS(2), Gary Cutter PhD(3), John Breitner MD, MPH(4), Gary Landreth PhD(5), Daniel Chain PhD(1)  
(1) CereSpir, Inc., New York, NY, USA, (2) Keck USC School of Medicine, Los Angeles, CA, USA, (3) University of Alabama, Birmingham School of Public Health, Birmingham, AL, USA, (4) Douglas Mental Health University Institute - Research Centre, McGill University, Montreal, PQ, Canada, (5) Case Western Reserve University, School of Medicine, Cleveland, OH, USA
POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, December 10

THEME 12: Clinical trials: recruitment and pre-screening

<table>
<thead>
<tr>
<th>POSTER</th>
<th>TITLE</th>
<th>AUTHORS</th>
<th>INSTITUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-30</td>
<td>PATIENT SELECTION FOR CNS CLINICAL TRIALS: FINDINGS FROM A 23,800-PATIENT ELIGIBILITY REVIEW DATABASE AND SUB-ANALYSIS OF ALZHEIMER DISEASE TRIALS</td>
<td>Robin C. Hillsabeck, PhD (1), Jennifer Murphy, PhD (1), Nadia Yakovleva, MD (1), Claire K. Reinhold (1), Katya Miloslavich (1), Jeffrey Holleran (1), Kari R. Nations, PhD (1)</td>
<td>INC Research, Austin, TX, USA</td>
</tr>
<tr>
<td>P3-31</td>
<td>EVALUATING CORRELATIONS BETWEEN RECRUITMENT RATES AND SITE RATINGS QUALITY</td>
<td>Miller, D (1), Wang, X (1), Allen, S (1), Gratkowski, H (1), Feaster, T (1), Butler, A (1)</td>
<td>(1) Bracket, Wayne, PA, USA</td>
</tr>
<tr>
<td>P3-32</td>
<td>RECRUITMENT PRACTICES FOR ENABLING RAPID PRECLINICAL ALZHEIMER'S DISEASE CLINICAL TRIALS ENROLLMENT: EXPERIENCE FROM THE TOMMORROW STUDY</td>
<td>Kathleen M. Hayden, PhD(1),1 Meredith Culp, BS3 Ryan Walter, BS(3) Patrick Harrigan, BChE,(3) Daniel K. Burns, PhD(1), Ferenc Martenyi, MD(3), Oksana Makeeva, PhD,(4) Allen D. Roses, MD(1,2) for the TOMMORROW investigators</td>
<td>(1) Duke University Bryan ADRC, Durham, NC, USA, (2) Zinfandel Pharmaceuticals, Inc., Durham, NC, USA, (3) Takeda Global Research &amp; Development Center, Inc., Deerfield, IL, USA, (4) Nebbiolo, LLC</td>
</tr>
<tr>
<td>P3-33</td>
<td>COMPUTERISED TESTING: APPLICATIONS IN RECRUITMENT AND MONITORING OF PATIENTS IN CLINICAL TRIALS</td>
<td>Francesca Cormack PhD(1), Nick Taptiklis(1), Jack Curtis(1), Rosemary Abbott PhD(1), Jennifer H Barnett PhD(1,3)</td>
<td>(1) Cambridge Cognition, Cambridge, UK, (2) Department of Physiology Development &amp; Neuroscience, University of Cambridge, UK, (3) Department of Psychiatry, University of Cambridge, UK</td>
</tr>
<tr>
<td>P3-34</td>
<td>RETHINKING INSTITUTIONAL REVIEW BOARD SUBMISSIONS FOR ONLINE CLINICAL TRIAL RECRUITMENT</td>
<td>Shannon Finley, MA(1), Derek Flenniken(1), Aaron Ulbricht(1), Monica Camacho(1), Juliet Fockler(1), R Scott Mackin PhD(1,2), Rachel L Nosheny PhD(1,3), Diana Truran(1), Michael W Weiner MD(1,3)</td>
<td>(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA, (2) UCSF Department of Psychiatry, San Francisco, CA, USA, (3) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA</td>
</tr>
<tr>
<td>P3-35</td>
<td>THE BRAIN HEALTH REGISTRY CAREGIVER AND STUDY PARTNER PORTAL TO FACILITATE ALZHEIMER'S CLINICAL TRIALS</td>
<td>Nosheny RL (1,3), Flenniken D(1), Camacho M(1), Ulbricht A, Fockler J(1), Insel PS(1,3), Mackin RS PhD(1,2), Truran D(1), Finley S(1), Mckenzie K(1), Weiner MW, (1,3)</td>
<td>(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA, USA, (2) UCSF Department of Psychiatry, San Francisco, CA, USA, (3) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA</td>
</tr>
</tbody>
</table>

THEME 13: Others

<table>
<thead>
<tr>
<th>POSTER</th>
<th>TITLE</th>
<th>AUTHORS</th>
<th>INSTITUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-36</td>
<td>REPRESENTATIVENESS OF WESTERN EUROPEAN CLINICAL TRIAL POPULATIONS IN MILD ALZHEIMER’S DISEASE DEMENTIA – A COMPARISON OF 18-MONTH OUTCOMES WITH REAL-WORLD DATA FROM THE GERAS OBSERVATIONAL STUDY</td>
<td>Antje Tockhorn-Heidenreich (1), Mark Belger (1), Graziella D’Agnello (2), Kristin Kahle Wroblewska (3,4), Gopalan Sentharamanan (3), David Henley (3,4), Ann Hake (3,4), Joel Raskin (3), Catherine Reed (1)</td>
<td>(1) Eli Lilly and Company Limited, Windlesham, UK, (2) Eli Lilly Italia, Sesto Fiorentino, Italy, (3) Eli Lilly and Company, Indianapolis, USA, (4) Indiana University School of Medicine, Indianapolis, USA</td>
</tr>
<tr>
<td>P3-37</td>
<td>THERAPEUTIC LINKS BETWEEN ANTI-CANCER DRUGS (BEXAROTENE) AND ALZHEIMER’S DISEASE</td>
<td>Krishna Prasad Pathak, PhD(1), Tara Gaire, RN(2), Magda Tsolaki, MD, PhD(3)</td>
<td>(1) Macedonia of University, Thessaloniki, Greece, (2) Star Hospital, Lalitpur, Nepal, (3) Department of Neurology, Aristotle University of Thessaloniki</td>
</tr>
<tr>
<td>P3-38</td>
<td>A NEW PARTNERSHIP TO CREATE A NATIONAL IRB FOR CLINICAL TRIALS IN DEMENTING ILLNESS</td>
<td>David S. Knopman, MD (1), Eli T. S. Alford, MS (2), Rebecca A. Ballard, JD, MA, CIP (3), Kaitlin E. Tate, BA (2), Ara S. Khachatryan, Ph.D.(4)</td>
<td>(1) Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA, (2) Schuman IRB, Research Triangle Park, North Carolina, USA, (3) Schuman IRB, Cincinnati, Ohio, USA, (4) National Biomedical Research Ethics Council, Las Vegas, Nevada, USA</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, December 10

THEME 13: Others (continued)

P3-39 LONGITUDINAL ANALYSIS OF [18F]THK5351 TAU PET IMAGES IN PATIENTS WITH ALZHEIMER’S DISEASE
Nobuyuki Okamura, MD, PhD(1) Ryuichi Harada, PhD(2,3), Aiko Ishiki, MD, PhD(2), Katsutoshi Furukawa, MD, PhD(1,2), Shozo Furumoto, PhD(4), Manabu Tashiro, MD, PhD(4), Kazuhiko Yanai, MD, PhD(3,4), Hiroyuki Arai, MD, PhD(2), Yukitsuka Kudo, PhD(2)
(1) Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan, (2) Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, (3) Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan, (4) Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan

P3-40 THE USE OF CONVERSATION ANALYSIS FOR INTERACTIONAL DESIGN WITHIN A LIVING LAB FRAMEWORK
Giovanni Carletti, PhD(1); Pierre Wargnier PhD(2); Samuel Benveniste(2), Pierre Jouvelot(2), Anne-Sophie Rigaud(3)
(1) LIAS - Institut Marcel Mauss, CNRS-EHESS, France, (2) MINES ParisTech, PSL Research University, France, (3) Broca Hospital, Assistance Publique - Hôpitaux de Paris, France

P3-41 ELABORATION OF A TOOL AIMING TO IDENTIFY SUBJECTS AT RISKS OF FRAILTY AND TO EVALUATE THE IMPACT OF PREVENTION MEASURES
Michel Noguès, PHD(1), Valérie Bruguière, MA(1), Justine Millot-Keurinck, MSc(1), Gabrielle Onorato, MSc(1), Sébastien Teissier (2), Jacques Touchon, MD, PHD(3), Jean-Claude Reuzeu, MA(1)
(1) Caisse Assurance Retraite et Santé Au Travail (Carsat) Languedoc-Roussillon, Montpellier, France (2) Resilient Innovation, Montpellier, France (3) University of Montpellier, France
General information

Welcome Reception
Thursday, December 8th
From 8 to 10:45 pm

CTAD 2016 and the USC Alzheimer’s Therapeutic Research Institute welcome you to San Diego!

Come join us on the Coronado Terrace at the Marriott Marquis. This beautiful outdoor venue overlooking the water, showcases breathtaking views of San Diego Bay and Coronado Island. Spend time meeting other attendees while enjoying great food and drinks!

Directions: The Coronado Terrace is located on the 4th Floor of the South Tower at the Marriott Marquis San Diego.

Conference Venue

Marriott Marquis San Diego Marina
333 West Harbor Drive
San Diego, California 92101 USA

Practical details:
Pre-registration - Marina Foyer - Level 3
Wednesday, December 7th 2 - 6 pm
To avoid the rush at the registration desk on Thursday morning we recommend you come pick up your badge and attendee’s bag the day before.

Registration desk opening hours:
The registration desk is located in the Marina Foyer - Level 3.
• Thursday, December 8th 6:30 am - 6:30 pm
• Friday, December 9th 6:30 am - 6:15 pm
• Saturday, December 10th 7:00 am - 12:30 pm

Meeting Room: Marina Ballroom DEFG - Level 3

Coffee Breaks, Lunches and Poster Sessions:
in the San Diego Ballroom - Lobby Level of the Hotel

This year 3 different poster sessions are presented during the event:
• POSTER SESSION 1: Thursday, December 8th
  P1-1 to P1-50
• POSTER SESSION 2: Friday, December 9th
  P2-1 to P2-44
• POSTER SESSION 3: Saturday, December 10th
  P3-1 to P3-41
CTAD 2016 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors

ACT-AD
Axovant
Biogen
Eisai
Janssen
Lilly
Merck
Otsuka
Pfizer
Roche

Clinical Trials
Clinical Trials on Alzheimer's Disease

November 2-4, 2017
BOSTON

www.ctad-alzheimer.com